Clinical trial NCT06132867
Conditions: Healthy Volunteers
Keywords: Drug Therapy
Sponsor: Takeda
Start date: 2023-12-20; Completion date: 2024-02-17
Enrollment: 12 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
The main aim of this study is to compare the amount of brigatinib in the blood of healthy adults after they have swallowed one dose either as a solution or as a tablet.

Detailed description:
The drug being tested in this study is called brigatinib. Brigatinib is being tested to assess its relative bioavailability when administered as an oral solution versus as an immediate-release tablet in healthy participants.

The study will enroll approximately 12 participants. Participants will be randomly assigned to one of the treatment sequences:

* Sequence 1: Treatment A followed by Treatment B
* Sequence 2: Treatment B followed by Treatment A wherein Treatment A is a 90 mg oral solution dose and Treatment B is a 90 mg tablet dose.

There will be a washout period of at least 14 days between brigatinib administration in each study period. The follow-up contact will occur 14 (±2) days post the last dose of study drug.

This single-center trial will be conducted in the United States. The overall study duration is approximately 56 days.

Arms: arm 1: Participants received single dose of brigatinib 90 milligram (mg) as an oral solution in a fasted state on Day 1 of Period 1 (Treatment A) followed by single dose of brigatinib 90 mg as an immediate-release tablet in a fasted state on Day 1 of Period 2 (Treatment B). A washout period of at least 14 days was maintained between brigatinib administration in Period 1 and 2. arm 2: Participants received single dose of brigatinib 90 mg as an immediate-release tablet in a fasted state on Day 1 of Period 1 (Treatment B) followed by single dose of brigatinib 90 mg as an oral solution in a fasted state on Day 1 of Period 2 (Treatment A). A washout period of at least 14 days was maintained between brigatinib administration in Period 1 and 2.
Interventions: intervention 1: Brigatinib intervention 2: Brigatinib
Intervention descriptions: intervention 1: Brigatinib oral solution intervention 2: Brigatinib tablet

Protocol documents:
Prot_000.pdf: 
For non-commercial use only


 
 
 
CONFIDENTIAL INFORMATION 
TAKEDA PHARMACEUTICALS 
PROTOCOL 
A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the 
Relative Bioavailability of Brigatinib Administered as an Oral Solution versus an 
Immediate-Release Tablet in Adult Healthy Subjects 
Study Identifier: 
Brigatinib-1004 
Compound: 
Brigatinib 
Date: 
05 Jan 2024 
Version/Amendment 
Number: 
Amendment 01 
Version/Amendment History: 
Date 
Amendment Number 
Amendment Type 
Region 
13 Sep 2023 
Initial Version 
Not Applicable 
United States 
05 Jan 2024 
01 
Substantial 
United States 
CONFIDENTIAL PROPERTY OF TAKEDA 
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement 
by the recipient that no information contained herein will be published or disclosed without written authorization 
from Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her 
staff, and applicable institutional review committee and regulatory agencies to enable conduct of the study. 
For non-commercial use only


Brigatinib 
Study No. Brigatinib-1004 
Page 2 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
CONFIDENTIAL 
TABLE OF CONTENTS 
1.0 
STUDY SUMMARY...........................................................................................................6 
2.0 
STUDY SCHEMATIC ......................................................................................................10 
3.0 
SCHEDULE OF STUDY PROCEDURES .......................................................................11 
4.0 
INTRODUCTION .............................................................................................................14 
4.1 
Background ..................................................................................................................14 
4.2 
Rationale for the Proposed Study ................................................................................15 
4.3 
Benefit/Risk Profile .....................................................................................................15 
5.0 
STUDY OBJECTIVES AND ENDPOINTS .....................................................................15 
5.1 
Hypothesis....................................................................................................................15 
5.2 
Study Objectives ..........................................................................................................15 
5.2.1 Study Primary Objective ........................................................................................15 
5.2.2 Study Secondary Objective ....................................................................................15 
5.3 
Endpoints .....................................................................................................................16 
5.3.1 Primary Endpoints .................................................................................................16 
5.3.2 Secondary Endpoints .............................................................................................16 
5.3.3 Exploratory Endpoints ...........................................................................................16 
6.0 
STUDY DESIGN AND DESCRIPTION ..........................................................................16 
6.1 
Study Design ................................................................................................................16 
6.2 
Dose Escalation ............................................................................................................17 
6.3 
Stopping Rules .............................................................................................................17 
6.4 
Rationale for Study Design, Dose, and Endpoints .......................................................18 
6.4.1 Rationale of Study Design .....................................................................................18 
6.4.2 Rationale for Dose .................................................................................................18 
6.4.3 Rationale for Endpoints .........................................................................................18 
6.4.4 Future Biomedical Research ..................................................................................18 
6.4.5 Critical Procedures Based on Study Objectives: Timing of Procedures................18 
6.5 
Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters ....................................................................................................................19 
6.6 
Study Beginning and End/Completion ........................................................................19 
6.6.1 Definition of Beginning of the Study.....................................................................19 
6.6.2 Definition of End of the Study ...............................................................................19 
6.6.3 Definition of Study Completion.............................................................................19 
6.6.4 Definition of Study Discontinuation ......................................................................19 
6.6.5 Criteria for Premature Termination or Suspension of the Study ...........................19 
For non-commercial use only


Brigatinib 
Study No. Brigatinib-1004 
Page 3 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
CONFIDENTIAL 
6.6.6 Criteria for Premature Termination or Suspension of a Site..................................20 
7.0 
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS ...............20 
7.1 
Inclusion Criteria .........................................................................................................20 
7.2 
Exclusion Criteria ........................................................................................................21 
7.3 
Excluded Medications, Supplements, Dietary Products ..............................................22 
7.4 
Diet, Fluid, Activity .....................................................................................................23 
7.4.1 Diet and Fluid ........................................................................................................23 
7.4.2 Activity ..................................................................................................................23 
7.5 
Criteria for Discontinuation or Withdrawal of a Subject .............................................23 
7.6 
Procedures for Discontinuation or Withdrawal of a Subject .......................................24 
7.7 
Subject Replacement ....................................................................................................24 
8.0 
CLINICAL STUDY MATERIAL MANAGEMENT .......................................................24 
8.1 
Clinical Study Drug .....................................................................................................24 
8.1.1 Clinical Study Drug Labeling ................................................................................24 
8.1.2 Clinical Study Drug Inventory and Storage ...........................................................25 
8.1.3 Clinical Study Drug Blinding ................................................................................25 
8.1.4 Randomization Code Creation and Storage ...........................................................25 
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure ....................................25 
8.1.6 Accountability and Destruction of Sponsor-Supplied Drugs.................................25 
9.0 
STUDY PROCEDURES ...................................................................................................25 
9.1 
Administrative Procedures ...........................................................................................25 
9.1.1 Informed Consent Procedure .................................................................................25 
9.1.2 Inclusion and Exclusion .........................................................................................26 
9.1.3 Medical History/Demography ...............................................................................26 
9.1.4 Concomitant Medications ......................................................................................26 
9.2 
Clinical Procedures and Assessments ..........................................................................26 
9.2.1 Full Physical Examination .....................................................................................26 
9.2.2 Height and Weight .................................................................................................26 
9.2.3 BMI ........................................................................................................................27 
9.2.4 Vital Signs ..............................................................................................................27 
9.2.5 12-Lead ECG .........................................................................................................27
9.2.6 Palatability Assessment .........................................................................................27 
9.2.7 Study Drug Administration ....................................................................................27 
9.2.8 AE Monitoring .......................................................................................................28 
9.2.9 Laboratory Procedures and Assessments ...............................................................28 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 4 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
9.3 
PK Samples ..................................................................................................................30 
9.3.1 PK Measurements ..................................................................................................30 
9.3.2 Biomarker Measurements ......................................................................................31 
9.3.3 PGx Measurements ................................................................................................31 
9.3.4 Confinement ...........................................................................................................31 
10.0 
ADVERSE EVENTS .........................................................................................................31 
10.1 
Definitions and Elements of AEs .................................................................................31 
10.1.1 SAEs ......................................................................................................................33 
10.1.2 Special Interest AEs ...............................................................................................34 
10.2 
AE Procedures .............................................................................................................35 
10.2.1 Assigning Severity/Intensity of AEs ......................................................................35 
10.2.2 Assigning Causality of AEs ...................................................................................35 
10.2.3 Start Date ...............................................................................................................35 
10.2.4 End Date.................................................................................................................36 
10.2.5 Pattern of Adverse Event (Frequency) ...................................................................36 
10.2.6 Action Taken With Study Treatment .....................................................................36 
10.2.7 Outcome .................................................................................................................36 
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal 
Liver Function Tests (LFT) ...................................................................................37 
10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities .....39 
11.0 
STATISTICAL METHODS ..............................................................................................40 
11.1 
Statistical and Analytical Plans ....................................................................................40 
11.1.1 Analysis Sets ..........................................................................................................40 
11.1.2 Analysis of Demography and Other Baseline Characteristics ...............................40 
11.1.3 PK Analysis ...........................................................................................................40 
11.1.4 PD Analysis ...........................................................................................................41 
11.1.5 Safety Analysis ......................................................................................................41 
11.2 
Palatability ...................................................................................................................41 
11.3 
Interim Analysis and Criteria for Early Termination ...................................................42 
11.4 
Determination of Sample Size .....................................................................................42 
12.0 
QUALITY CONTROL AND QUALITY ASSURANCE .................................................42 
12.1 
Study-Site Monitoring Visits .......................................................................................42 
12.2 
Protocol Deviations ......................................................................................................42 
12.3 
Quality Assurance Audits and Regulatory Agency Inspections ..................................43 
13.0 
ETHICAL ASPECTS OF THE STUDY ...........................................................................43 
13.1 
IRB and/or IEC Approval ............................................................................................43 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 5 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
13.2 
Subject Information, Informed Consent, and Subject Authorization ..........................44 
13.3 
Subject Confidentiality ................................................................................................45 
13.4 
Publication, Disclosure, and Clinical Study Registration Policy .................................45 
13.4.1 Publication and Disclosure ....................................................................................45 
13.4.2 Clinical Study Registration ....................................................................................46 
13.4.3 Clinical Study Results Disclosure ..........................................................................46 
13.5 
Insurance and Compensation for Injury .......................................................................46 
14.0 
ADMINISTRATIVE AND REFERENCE INFORMATION ...........................................47 
14.1 
Administrative Information .........................................................................................47 
14.1.1 Study Contact Information .....................................................................................47 
14.1.2 INVESTIGATOR AGREEMENT.........................................................................48 
14.1.3 Study-Related Responsibilities ..............................................................................49 
14.1.4 List of Abbreviations .............................................................................................49 
15.0 
DATA HANDLING AND RECORDKEEPING ..............................................................51 
15.1 
CRFs (Electronic and Paper) .......................................................................................51 
15.2 
Record Retention .........................................................................................................51 
16.0 
REFERENCES ..................................................................................................................52 
17.0 
APPENDICES ...................................................................................................................53 
 
LIST OF IN-TEXT TABLES 
Table 1.a: 
Description of Treatment Sequences in the Study ...................................................6 
Table 6.a: 
Description of Treatment Sequences in the Study .................................................17 
Table 6.b: 
Planned Brigatinib Dose Levels/Treatments .........................................................17 
Table 7.a 
Excluded Medications, Supplements, and Dietary Products .................................22 
Table 9.a: 
Primary Specimen Collections ...............................................................................30 
Table 10.a: 
Takeda Medically Significant AE List ..................................................................34 
 
LIST OF APPENDICES 
Appendix A 
Responsibilities of the Investigator ........................................................................53 
Appendix B 
Elements of the Subject Informed Consent ...........................................................55 
Appendix C 
Investigator Consent to the Use of Personal Information ......................................58 
Appendix D 
Pregnancy and Contraception ................................................................................59 
Appendix E 
Detailed Description of Amendments to Text .......................................................62 
 
For non-commercial use only


Brigatinib 
Study No. Brigatinib-1004 
Page 6 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
CONFIDENTIAL 
1.0 
STUDY SUMMARY 
Name of Sponsor: 
Takeda Development Center Americas, Inc. (TDCA) 
95 Hayden Avenue 
Lexington, Massachusetts 02421 
Telephone: +1 (617) 679-7000 
Compound: 
Brigatinib 
Study Identifier: Brigatinib-1004 
Phase: 1 
Protocol Title: A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the 
Relative Bioavailability of Brigatinib Administered as an Oral Solution versus an Immediate-Release Tablet in 
Adult Healthy Subjects  
Study Design: 
This is an open-label, randomized, 2-period, 2-sequence, crossover study in healthy adult subjects to evaluate the 
relative bioavailability of brigatinib when administered as an oral solution versus as an immediate-release tablet 
ALUNBRIG®.  
•
Treatment A (test formulation): 90 mg oral solution dose of brigatinib administered in a fasted state
•
Treatment B (reference formulation): 90 mg tablet dose of brigatinib administered in a fasted state
Approximately 12 subjects will be randomly assigned in a 1:1 ratio to one of the treatment sequences, as part of a 
crossover design (Table 1.a): 
Table 1.a: 
Description of Treatment Sequences in the Study 
Sequence 
Approximate number 
of subjects 
Period 1 
Period 2 
AB 
6 
A 
B 
BA 
6 
B 
A 
A= Oral solution dose of brigatinib, fasted state; B= Tablet dose of brigatinib, fasted state. 
Subjects will be admitted to the clinical facility on Day -1, the day prior to brigatinib administration in each 
dosing period. On Day 1 of each period, a single 90 mg dose of brigatinib will be administered. Blood samples 
for the measurement of plasma concentrations of brigatinib will be collected predose and up to 168 hours 
postdose following each brigatinib dose. For each dosing period, subjects will be housed starting on Day-1, at the 
time indicated by the Clinical Research Unit (CRU), until the morning of Day 4 after the 72 hour postdose blood 
draw and/or study procedures (Section 9.3.4). There will be a washout period of at least 14 days between 
brigatinib administration in each study period. Subjects will return for dosing and/or study procedures as 
indicated in Section 3.0, Schedule of Study Procedures. At all times, a subject may be required to remain at the 
CRU for longer at the discretion of the Investigator or designee. As per site preference, subjects may be confined 
throughout the study (ie, washout period and/or return visit[s]).  
The follow-up contact will occur 14 (±2) days post the last dose of study drug by telephone. If abnormal, 
potentially clinically significant findings are noted during this phone follow-up, subjects may then be brought 
back to the clinic for re-evaluation per the Investigator’s discretion. Serious adverse events (SAEs) should be 
followed up until resolution or permanent outcome. 
Study Primary Objective: 
•
To determine the relative bioavailability of brigatinib after single-dose administration of an oral solution
formulation versus an immediate-release tablet formulation.
Study Secondary Objective: 
For non-commercial use only


Brigatinib 
Study No. Brigatinib-1004 
Page 7 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
CONFIDENTIAL 
•
To evaluate the safety and tolerability of brigatinib after single-dose administration of an oral solution
formulation and an immediate-release tablet formulation.
Study Subject Population: Healthy male or female (of non-childbearing potential) subjects aged 18 to 55 years 
inclusive, at screening. Body Mass Index (BMI) ≥18.0 and ˂32.0 kg/m2, at screening.  
Planned Number of Subjects: 
Approximately 12 subjects will be enrolled 
Planned Number of Sites: 
1 
Dose Levels: 
Treatment A: Brigatinib 90 mg oral solution 
Treatment B: Brigatinib 90 mg tablet 
Route of Administration: 
Oral 
Duration of Treatment: 
Single-dose on Day 1 of each period 
Planned Study Duration: 
Approximately 56 ± 2 days including the following: 
Screening: Up to 4 weeks (28 days) 
Dosing Period: Two (2) dosing periods (with a minimum 
14-day washout period between doses)
Safety Follow-Up: 14 (± 2) days post last dose of study 
drug 
Criteria for Inclusion: 
Subjects must fulfill the following inclusion criteria to be eligible for participation in the study: 
1.
Healthy, adult, males or females (of non-childbearing potential), 18-55 years of age, inclusive, at screening.
2.
A nonvasectomized male subject must agree to use a condom with spermicide or abstain from sexual
intercourse during the study until at least 3 months after the last study drug dosing. (No restrictions are
required for a vasectomized male provided his bilateral vasectomy procedure has been performed at least
1 year prior to the first dosing of study drug. A male who has been vasectomized less than 1 year prior to
study first dosing must follow the same restrictions as a nonvasectomized male). A vasectomized subject
may not use vasectomy as his primary/only form of contraception if he is unable to provide the surgical
documentation (refer to Appendix D).
3.
Male subjects must agree not to donate sperm from the first dosing until at least 3 months and female
subjects must agree not to donate ova from the first dosing until at least 4 months after the last study drug
dosing.
4.
Female subjects of non-childbearing potential must have undergone one of the following sterilization
procedures at least 6 months prior to dosing (hysteroscopic sterilization, bilateral tubal ligation, bilateral
salpingectomy, hysterectomy, or bilateral oophorectomy); or be postmenopausal with amenorrhea for at least
1 year prior to dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal
status (refer to Appendix D).
5.
Continuous nonsmoker who has not used nicotine-containing products for at least 3 months prior to the first
dosing and throughout the study.
6.
BMI ≥18.0 and ˂32.0 kg/m2 at screening.
7.
Medically healthy with no clinically significant medical history or abnormalities in physical examination,
laboratory profiles, vital signs or 12-lead electrocardiograms (ECGs) performed at the screening visit and
before administration of the initial dose of trial drug, as deemed by the Investigator or designee.
8.
Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with
the protocol.
9.
Pulse rate between 60 and 100 bpm and a blood pressure between 90 to 140 mmHg systolic and 40 to
90 mmHg diastolic at screening and prior to dosing of Period 1.
For non-commercial use only


Brigatinib 
Study No. Brigatinib-1004 
Page 8 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
CONFIDENTIAL 
10. Creatine phosphokinase is ≤1.1x upper limit of normal [ULN]; lipase, amylase, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total bilirubin, glucose, and activated partial thromboplastin time
(aPTT) are ≤ULN at screening and check-in of Period 1.
Criteria for Exclusion: 
Subjects must not be enrolled in the study if they meet any of the following criteria: 
1.
Is mentally or legally incapacitated or has significant emotional problems at the time of the screening
visit or expected during the conduct of the study.
2.
History or presence of clinically significant endocrine, gastrointestinal (including motility disorder and
intestinal obstruction), cardiovascular, hematological, hepatic, immunological, renal, respiration,
genitourinary, major neurological (including stroke and chronic seizures), or malignancy, active
infectious diseases, ophthalmologic disorders other than presbyopia/myopia/hyperopia/astigmatism, or
any other clinically significant abnormalities or disease in the opinion of the Investigator or designee.
3.
Any history of major surgery, eg, cholecystectomy, intestinal resections, hepatectomy, nephrectomy,
digestive organ resection that may affect absorption, metabolism or excretion of study drug. A history of
appendectomy is not exclusionary.
4.
History of any illness that, in the opinion of the Investigator or designee, might confound the results of
the study or poses an additional risk to the subject by their participation in the study.
5.
History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
6.
History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
7.
Positive urine drug or cotinine, or alcohol results at screening or check-in.
8.
Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen
(HBsAg), or hepatitis C virus (HCV).
9.
Positive COVID-19 results at first check-in.
10. Currently has an active infection, in the opinion of the Investigator.
11. QT interval corrected for heart rate using Fridericia's formula (QTcF) is >460 msec or ECG findings are
deemed abnormal with clinical significance by the Investigator or designee at screening.
12. Estimated creatinine clearance <90 mL/minute at screening (calculated using the Cockcroft-Gault
formula).
13. Unable to refrain from or anticipates the use of any drug, including prescription and nonprescription
medications, herbal remedies, or vitamin supplements within 28 days prior to the first dosing and
throughout the study. Acetaminophen (up to 2 g per 24-hour period) may be permitted during the study,
only after the first dosing, at the discretion of the Investigator or designee, as medically indicated.
Thyroid hormone replacement medication may be permitted if the subject has been on the same stable
dose for the immediate 3 months prior to the first dosing.
14. Has been on a diet incompatible with the on-study diet, including consumption of grapefruit juice and
other grapefruit containing products, in the opinion of the Investigator or designee, within the 30 days
prior to the first dosing and throughout the study.
15. Donation of blood or significant blood loss within 56 days prior to the first dosing.
16. Plasma donation within 7 days prior to the first dosing.
17. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be
derived from the date of the last blood collection or dosing, whichever is later, in the previous study to
Day 1 of Period 1 of the current study.
Main Criteria for Evaluation and Analyses: 
Primary Endpoints: 
The primary endpoints for this study are brigatinib pharmacokinetic (PK) parameters after a single-dose of an 
oral solution formulation and an immediate-release tablet formulation, including: 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 9 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• 
Maximum observed plasma concentration (Cmax); 
• 
Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable 
concentration (AUClast); 
• 
Area under the plasma concentration-time profile from time 0 to infinity (AUC). 
Secondary Endpoints: 
The secondary endpoints will be assessed through evaluation of the following parameters:  
• 
Number of subjects with at least one treatment-emergent adverse event (TEAE) and/or serious adverse 
event (SAE). 
Exploratory Endpoints: 
The following PK parameters for brigatinib after administration of each formulation: 
• 
Time of first occurrence of Cmax (tmax); 
• 
Apparent clearance after extravascular administration (CL/F); 
• 
Apparent volume of distribution during the terminal disposition phase after extravascular administration 
(Vz/F); 
• 
Terminal disposition phase half-life (t½z); 
• 
Terminal disposition phase rate constant (λz); 
• 
The area under the curve from the last quantifiable concentration to infinity, expressed as a percentage 
of AUC (AUC%extrap). 
Data related to the acceptability and palatability of the oral solution formulation will also be collected. 
Statistical Considerations: 
Plasma PK parameters of brigatinib will be derived using standard noncompartmental analysis methods. A linear 
mixed-effects analysis of variance model will be used for the analysis on the natural log (ln)-transformed 
brigatinib PK parameters (Cmax, AUClast, and AUC). The model will include sequence, treatment, and period as 
fixed effects. Subject nested within sequence will be included as a random effect. Each model will include 
calculation of least squares means (LSM) as well as the difference between treatment LSM. Geometric mean 
ratios (GMR) and 90% confidence intervals (CIs) will be calculated using the exponentiation of the difference 
between treatment LSM from the analyses on the ln-transformed Cmax, AUClast, and AUC. These ratios will be 
expressed as a ratio of the test treatment (ie, oral solution) relative to the reference treatment (ie, tablet).  
Sample Size Justification:  
The sample size calculation was based on the expected 2-sided 90% CIs for the difference in the paired, 
ln-transformed AUC means of brigatinib after administration as an oral solution versus an immediate-release 
tablet. The within-subject percent coefficient of variation (%CV) for brigatinib AUC was estimated to be 
12% on the basis of data from previous clinical studies conducted in healthy subjects (Studies AP26113-15-106 
and AP26113-16-110). If the observed GMR for brigatinib AUC after administration as an oral solution versus a 
tablet is 1, with a sample size of 8, the 90% CIs for the GMR is expected to be 0.89 to 1.12 on the basis of the 
variance assumptions. 
It is anticipated that a total of approximately 12 subjects will be enrolled to obtain at least 8 PK-evaluable 
subjects. Subjects will be randomized into 2 treatment sequences, as indicated in Table 1.a.  
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 10 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
2.0 
STUDY SCHEMATIC 
Pretreatment 
Treatment Periods 1 & 2 (a) 
Follow-up (c) 
Screening 
Check-in (b) 
(Periods 1 & 2) 
Dosing and 
Study Assessments 
PK Assessments 
Within 28 
days of first 
dosing 
Day -1 
Day 1 
Days 1-4 (d) 
Days 6 & 8 (d) 
14 (±2) Days 
following last 
dose 
 
 Confinement (d)       
 
 
(a) There will be a washout period of at least 14 days between brigatinib administration in each study period. 
(b) Subjects will be admitted on Day -1.  
(c) The follow-up contact will occur 14 (±2) days after the last dose. 
(d) For each dosing period, subjects will be housed starting on Day-1, at the time indicated by the CRU, until the morning 
of Day 4, after the 72 hours postdose blood draw and/or study procedures (Section 9.3.4). Subjects will return for 
study procedures on Days 6 and 8. As per site preference, subjects may be confined throughout the study (ie, washout 
period[s] and/or return visit[s]). 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 11 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
3.0 
SCHEDULE OF STUDY PROCEDURES 
Study 
Procedu
re↓ 
 
Scr 
 
Study Days of Periods 1 and 2a 
ET 
Safet
y F/U 
Callp 
Study 
Day→ 
Day-28 
to Day 
1 
dosing 
Day -1 
Day 1 
Day 
2 
Day 
3 
Day 
4 
Day 
6 
Day 
8 
Hours→ 
 
Check-
inb 
Predo
se 
0 
0.25 
0.5 
1 
1.5 
2 
4 
6 
8 
12 
24 
48 
72 
120 
168 
Administrative Procedures 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
Criteria 
X 
Xc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical 
History/Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prior and Concomitant 
Medication 
X 
------------------------------------  Continuous Monitoring  ----------------------------- 
X 
Clinical Procedures/Assessments 
Full Physical 
Examinationd 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
Xo 
X 
 
Height, BMI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supine Safety 12-lead 
ECGf 
X 
 
Xe 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
Xo 
X 
 
Semi-Recumbent Vital 
Signs (Pulse Rate, 
Systolic Blood Pressure 
and Diastolic Blood 
Pressure)g 
X 
 
Xe 
 
 
 
X 
 
 
X 
 
 
 
X 
X 
X 
X 
Xo 
X 
 
Vital signs (Respiratory 
Rate, Oral [at the floor 
of the mouth] or 
Tympanic 
Temperature)g 
X 
 
Xe 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
 
Xo 
X 
 
Dosing of Brigatinibh 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE Monitoring 
X 
----------------------------------------------------- Continuous Monitoring ---------------------------------------------------- 
Laboratory Procedures/Assessments 
Hematology 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
Xo 
X 
 
Urinalysis 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xo 
X 
 
Chemistryi 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
Xo 
X 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 12 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Study 
Procedu
re↓ 
 
Scr 
 
Study Days of Periods 1 and 2a 
ET 
Safet
y F/U 
Callp 
Study 
Day→ 
Day-28 
to Day 
1 
dosing 
Day -1 
Day 1 
Day 
2 
Day 
3 
Day 
4 
Day 
6 
Day 
8 
Hours→ 
 
Check-
inb 
Predo
se 
0 
0.25 
0.5 
1 
1.5 
2 
4 
6 
8 
12 
24 
48 
72 
120 
168 
Coagulation 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
Xo 
X 
 
Serum Pregnancy Testj 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xo 
X 
 
Serum FSHj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine Drug Screen 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine Cotinine Screen 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine Alcohol Testk 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serology (HBsAg, 
HCV, HIV) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COVID-19 Screen 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacokinetics Evaluations 
Blood Sample for PKl 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Other Procedures 
Palatability 
Questionnaire 
(Treatment A only) 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confinement 
 
Xm 
 
 
 
 
Discharge from CRU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xn 
 
 
 
 
Outpatient Visit 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
 
Abbreviations: AE = Adverse events, BMI = Body mass index, COVID-19 = Coronavirus Disease 2019, CRU = Clinical research unit, ECG = Electrocardiogram, ET = Early termination, 
FSH = Follicle stimulating hormone, F/U = Follow-up, HCV = Hepatitis C virus, HBsAg = Hepatitis B surface antigen, HIV = Human immunodeficiency virus, PK = Pharmacokinetics, Scr 
= Screening 
a 
There will be a washout period of at least 14 days between brigatinib doses in each study period.  
b 
Subjects will be admitted on Day -1. 
c 
To be performed in Period 1 only. 
d 
Symptom-driven physical examinations may be performed at other times, at the Investigator’s or designee’s discretion.  
e 
Predose assessments on Day 1 of Period 1 and Period 2 may be done within approximately 24 hours prior to study drug administration. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 13 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
f 
Single ECG will be conducted. Subject should have rested in a supine position for at least 5 minutes before ECG measurement. When ECG coincides with other assessments post 
brigatinib administration, the sequence of procedures will be PK sampling, safety ECG, vital signs assessment, and then the safety laboratory blood draw. 
g 
Postdose vital sign (ie, pulse rate, systolic blood pressure, diastolic blood pressure, respiratory rate, and oral or tympanic temperature) will be measured at times relative to the brigatinib 
dosing. Subjects should have rested in a semi-recumbent position for at least 5 minutes before the measurements are acquired at all timepoints including screening. 
h 
Dosing will occur at the CRU based on the treatment that the subjects are randomized to receive within a study period (Treatment A or B). Treatment A: 90 mg oral solution dose of 
brigatinib  
(ie, 9 mL of the 10 mg/mL solution) immediately followed by approximately 240 mL (8 fluid ounces) of water. Treatment B: 90 mg tablet dose of brigatinib (ie, one 90 mg tablet) with 
approximately 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours postdose in each period, water is allowed as desired except for one hour before and one 
hour after study drug administration and as dosing water.  
i 
Serum chemistry tests will be performed after at least an 8-hour fast with the exception of the Hour 8 postdose laboratory assessment on Day 1; however, in case of dropouts or 
rechecks, subjects may not have fasted for 8 hours prior to when the serum chemistry sample is being taken. 
j 
Serum pregnancy tests are to be performed for all females and serum FSH tests are to be performed for all postmenopausal females only. 
k 
A urine alcohol test will be performed at the indicated scheduled timepoints and at the discretion of the Investigator, as applicable.  
l 
PK blood samples for the measurement of plasma concentrations of brigatinib will be collected starting Day 1 in Period 1 and Period 2 at times relative to the brigatinib dose (Hour 0).  
m 
Subjects will be confined from Day -1 until after the Day 4 study assessments are completed in each period. As per site preference, subjects may be confined throughout the study (ie, 
washout period and/or return visit[s]). 
n 
Discharge will occur on the morning of Day 4 after collection of the 72 hour PK sample and/or study procedures, unless the subject will be confined for a longer duration at the 
discretion of the Investigator. 
o 
To be performed at the end of Period 2 only. 
p 
The F/U contact will occur 14 (±2) days after the last dose of the study drug. 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 14 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
4.0 
INTRODUCTION 
4.1 
Background 
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of adult 
patients with ALK-positive advanced non-small cell lung cancer (NSCLC). The recommended 
clinical dose of brigatinib in adults is 90 mg once daily (QD) for 7 days, followed by 180 mg QD 
thereafter. ALK is also known to play a role in inflammatory myofibroblastic tumor and 
anaplastic large cell lymphoma, two cancers that occur in pediatric patients. Pediatric 
development of brigatinib is planned; however, brigatinib is currently available only as an 
immediate release tablet formulation in strengths of 30 mg, 90 mg, and 180 mg. Therefore, an 
age appropriate formulation of brigatinib has been developed and consists of an oral solution at a 
strength of 10 mg/mL. 
In addition to PK characterization in patients with cancer, a total of 10 clinical pharmacology 
studies have been completed for brigatinib. Seven (7) clinical pharmacology studies in healthy 
subjects have been completed to assess single-dose PK, drug-drug interaction potential, food 
effects, mass balance, metabolism and excretion, potential ethnic differences in PK, and 
bioequivalence of tablets of different strengths. Two studies have been completed to evaluate the 
PK of brigatinib in subjects with organ impairment (renal and hepatic impairment) in comparison 
with healthy subjects. Additionally, one clinical pharmacology study evaluated the effect of 
repeat dose administration of brigatinib on the PK of the sensitive cytochrome P450 (CYP) 3A 
substrate, midazolam, in patients with cancer. 
Brigatinib exhibits linear PK after single- and multiple-dose administration and dose 
proportional increases in exposure have been observed over the dose range of 60 mg to 240 mg. 
The median tmax of brigatinib ranges from 1-4 hours postdose and a high-fat meal was found to 
have no clinically meaningful effect on systemic exposure. The mean apparent oral clearance at 
steady-state is 8.9 L/h and the mean plasma elimination half-life is 25 hours. In the human 
absorption, distribution, metabolism and excretion study, 65% of the administered dose was 
recovered in the feces and 25% of the administered dose was recovered in the urine. 
CYP3A-mediated metabolism is considered to be the primary contributor to brigatinib systemic 
clearance in humans, with additional contributions from CYP2C8 and renal clearance. Results 
from in vitro transporter studies indicated that brigatinib is a substrate of P-glycoprotein and 
breast cancer resistance protein (BCRP) [1]. 
The most common adverse reactions (≥25%) reported for brigatinib are nausea, diarrhea, fatigue, 
cough, and headache. Also reported with brigatinib administration is interstitial lung 
disease/pneumonitis, hypertension, bradycardia, elevated creatine phosphokinase, visual 
disturbance, elevated pancreatic enzymes, hyperglycemia, and embryofetal toxicity [1, 2]. 
Testicular toxicity was observed in repeat-dose animal studies. In rats, findings included lower 
weight of testes, seminal vesicles and prostate gland, and testicular tubular degeneration; these 
effects were not reversible during the 2 month recovery period. In monkeys, findings included 
reduced size of testes along with microscopic evidence of hypospermatogenesis; these effects 
were reversible during the recovery period [2]. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 15 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Refer to the Investigator's Brochure [1] and the United States Prescribing Information [2] for 
additional information regarding brigatinib. 
4.2 
Rationale for the Proposed Study 
The purpose of this relative bioavailability study is to compare the PK of brigatinib following a 
single dose of 90 mg of the oral solution relative to a 90 mg dose of the immediate-release tablet 
formulation in adult healthy subjects. Brigatinib is currently available as an immediate-release 
tablet and is approved for the treatment of adult patients with ALK-positive advanced NSCLC. 
However, clinical studies in pediatric patients are planned. Therefore, an oral solution 
formulation has been developed to support administration of brigatinib to pediatric patients who 
are unable to swallow solid oral dosage forms. The results of this relative bioavailability study 
will subsequently be used to inform dose selection for the oral solution in the pediatric 
development program. 
4.3 
Benefit/Risk Profile 
The dose of brigatinib will be administered according to the product label and the adult dosing 
recommendations found therein [1, 2]. 
There will be no direct health benefit for study subjects from receipt of study drugs. An indirect 
health benefit to the healthy subjects enrolled in this study is the free medical tests received at 
screening and during the study. 
The inclusion and exclusion criteria, screening, and safety monitoring practices employed by this 
protocol (ie, 12-lead ECG, vital signs, clinical laboratory tests, AE questioning, and physical 
examination) are adequate to protect the subject’s safety and should detect all TEAEs. 
5.0 
STUDY OBJECTIVES AND ENDPOINTS 
5.1 
Hypothesis 
Not applicable 
5.2 
Study Objectives 
5.2.1 
Study Primary Objective 
To determine the relative bioavailability of brigatinib after single-dose administration of an oral 
solution formulation versus an immediate-release tablet formulation. 
5.2.2 
Study Secondary Objective 
To evaluate the safety and tolerability of brigatinib after single-dose administration of an oral 
solution formulation and an immediate-release tablet formulation. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 16 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
5.3 
Endpoints 
5.3.1 
Primary Endpoints 
The primary endpoints for this study are brigatinib PK parameters after a single-dose of an oral 
solution formulation and an immediate-release tablet formulation, including: 
• Cmax 
• AUClast 
• AUC 
5.3.2 
Secondary Endpoints  
The secondary endpoints will be assessed through evaluation of the following parameters:  
• Number of subjects with at least one TEAE and/or SAE. 
5.3.3 
Exploratory Endpoints 
The following PK parameters for brigatinib after administration of each formulation: 
• tmax 
• CL/F 
• Vz/F 
• t½z 
• λz 
• AUC%extrap 
Data related to the acceptability and palatability of the oral solution formulation will also be 
collected. 
6.0 
STUDY DESIGN AND DESCRIPTION 
6.1 
Study Design  
This is an open-label, randomized, 2-period, 2-sequence, crossover study in healthy adult 
subjects to evaluate the relative bioavailability of brigatinib when administered as an oral 
solution versus as an immediate-release tablet (ALUNBRIG®).  
• Treatment A (test formulation): 90 mg oral solution dose of brigatinib administered in a 
fasted state 
• Treatment B (reference formulation): 90 mg tablet dose of brigatinib administered in a 
fasted state 
Approximately 12 subjects will be randomly assigned in a 1:1 ratio to one of the treatment 
sequences, as part of a crossover design (Table 6.a): 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 17 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Table 6.a: 
Description of Treatment Sequences in the Study 
Sequence 
Approximate number of 
subjects 
Period 1 
Period 2 
AB 
6 
A 
B 
BA 
6 
B 
A 
A= Oral solution dose of brigatinib, fasted state; B= Tablet dose of brigatinib, fasted state. 
 
Subjects will be admitted to the clinical facility on Day -1, the day prior to brigatinib 
administration in each dosing period. On Day 1 of each period, a single 90 mg dose of brigatinib 
will be administered. Blood samples for the measurement of plasma concentrations of brigatinib 
will be collected predose and up to 168 hours postdose following each brigatinib dose. For each 
dosing period, subjects will be housed starting on Day -1, at the time indicated by the CRU, until 
the morning of Day 4 after the 72 hour postdose blood draw and/or study procedures 
(Section 9.3.4). There will be a washout period of at least 14 days between brigatinib 
administration in each study period. Subjects will return for dosing and/or study procedures as 
indicated in Section 3.0, Schedule of Study Procedures. At all times, a subject may be required to 
remain at the CRU for longer at the discretion of the Investigator or designee. As per site 
preference, subjects may be confined throughout the study (ie, washout period and/or return 
visit[s]).  
The follow-up contact will occur 14 (±2) days post the last dose of study drug by telephone. If 
abnormal, potentially clinically significant findings are noted during this phone follow-up, 
subjects may then be brought back to the clinic for re-evaluation per the Investigator’s discretion. 
SAEs should be followed up until resolution or permanent outcome. 
The planned dose levels/treatments of brigatinib to be evaluated are outlined in Table 6.b.  
Table 6.b: 
Planned Brigatinib Dose Levels/Treatments 
Treatment 
Brigatinib Dose 
Formulation 
State 
A 
90 mg 
Oral Solution 
Fasted 
B 
90 mg 
Tablet 
Fasted 
 
6.2 
Dose Escalation 
Not applicable.  
6.3 
Stopping Rules 
Enrollment and dosing will be suspended if Grade ≥3 adverse events (AE) considered at least 
possibly related to the study drug are observed in two participants in a dosing cohort (refer to 
Section 10.2.1 and 10.2.2) after review by the Investigator and the Sponsor. If appropriate, the 
protocol will be amended after safety review. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 18 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
6.4 
Rationale for Study Design, Dose, and Endpoints 
6.4.1 
Rationale of Study Design  
An oral solution formulation has been developed to support administration of brigatinib to 
pediatric patients who are unable to swallow solid oral dosage forms. The purpose of this relative 
bioavailability study is to compare the PK of brigatinib following a single dose of 90 mg of the 
oral solution relative to a 90 mg dose of the immediate-release tablet formulation in adult healthy 
subjects. The results of this study will subsequently be used to inform dose selection for the oral 
solution in the pediatric development program. 
6.4.2 
Rationale for Dose  
A 90 mg oral dose of brigatinib was selected for this study based on the following 
considerations:  
• Brigatinib exhibits linear PK over the dose range of 60 mg to 240 mg;  
• The 90 mg QD dose of brigatinib is the recommended starting dose in adult patients with 
NSCLC, which if tolerated for 7 days, is escalated to 180 mg QD thereafter;  
• Single doses as high as 180 mg of brigatinib have been previously administered to adult 
healthy subjects during development and have been found to be safe and generally 
well-tolerated.  
However, because brigatinib systemic exposures with the oral solution may be higher than those 
observed with the tablet, this relative bioavailability study will utilize a 90 mg brigatinib dose in 
order to allow for the achievement of the scientific objectives of the study while minimizing the 
potential risks to study subjects. 
6.4.3 
Rationale for Endpoints 
6.4.3.1 
Pharmacokinetic Endpoints 
The PK endpoints are standard for this type of relative bioavailability study. 
6.4.3.2 
Safety Endpoints 
The key safety endpoints are typical for Phase 1 studies. 
6.4.4 
Future Biomedical Research 
Not applicable. 
6.4.5 
Critical Procedures Based on Study Objectives: Timing of Procedures  
For this study, the critical component is the blood sample collection for the measurement of 
plasma concentrations of brigatinib, and the samples are to be collected as close to the scheduled 
times defined in this protocol as possible. When an ECG event coincides with other assessments, 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 19 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
the sequence of procedures will be PK sampling, safety ECG, vital signs assessment, and then 
the safety laboratory blood draw. 
6.5 
Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters 
The dose and administration of the study drugs to any subject may not be modified. If necessary, 
a subject may be discontinued for the reasons described in Section 7.5 and Section 7.6 
Unscheduled procedures might be performed for safety reasons. 
6.6 
Study Beginning and End/Completion 
6.6.1 
Definition of Beginning of the Study 
The beginning of the study will be defined as the beginning of the screening (i.e., signing of the 
ICF) of the first subject. 
6.6.2 
Definition of End of the Study 
The end of study is defined as the date of the last scheduled study procedure as outlined in the 
Schedule of Study Procedures (Section 3.0). 
6.6.3 
Definition of Study Completion 
The end of the study is scheduled after completion of the evaluations in the follow-up contact for 
the last subject in the study. 
This time period may change in the event that the study is terminated early or the last subject is 
lost to follow-up.  
6.6.4 
Definition of Study Discontinuation 
Celerion reserves the right to terminate the study in the interest of subject welfare. 
The Sponsor reserves the right to suspend or terminate the study at any time. 
6.6.5 
Criteria for Premature Termination or Suspension of the Study 
The study will be completed as planned unless one or more of the following criteria are satisfied 
that require temporary suspension or early termination of the study: 
• New information or other evaluation regarding the safety or efficacy of the study medication 
that indicates a change in the known risk/benefit profile for the product, such that the risk is 
no longer acceptable for subjects participating in the study. 
• Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises subject safety. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 20 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
6.6.6 
Criteria for Premature Termination or Suspension of a Site 
Not applicable. 
7.0 
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS 
7.1 
Inclusion Criteria 
Criteria for Inclusion: 
Subjects must fulfill the following inclusion criteria to be eligible for participation in the study:  
1. Healthy, adult, males or females (of non-childbearing potential), 18-55 years of age, 
inclusive, at screening. 
2. A nonvasectomized male subject must agree to use a condom with spermicide or abstain 
from sexual intercourse during the study until at least 3 months after the last study drug 
dosing. (No restrictions are required for a vasectomized male provided his bilateral 
vasectomy procedure has been performed at least 1 year prior to the first dosing of study 
drug. A male who has been vasectomized less than 1 year prior to study first dosing must 
follow the same restrictions as a nonvasectomized male). A vasectomized subject may not 
use vasectomy as his primary/only form of contraception if he is unable to provide the 
surgical documentation (refer to Appendix D).  
3. Male subjects must agree not to donate sperm from the first dosing until at least 3 months 
and female subjects must agree not to donate ova from the first dosing until at least 
4 months after the last study drug dosing. 
4. Female subjects of non-childbearing potential must have undergone one of the following 
sterilization procedures at least 6 months prior to dosing (hysteroscopic sterilization, 
bilateral tubal ligation, bilateral salpingectomy, hysterectomy, or bilateral oophorectomy); 
or be postmenopausal with amenorrhea for at least 1 year prior to dosing and FSH serum 
levels consistent with postmenopausal status (refer to Appendix D).  
5. Continuous nonsmoker who has not used nicotine-containing products for at least 
3 months prior to the first dosing and throughout the study. 
6. BMI ≥18.0 and ˂32.0 kg/m2 at screening.  
7. Medically healthy with no clinically significant medical history or abnormalities in 
physical examination, laboratory profiles, vital signs or 12-lead ECGs performed at the 
screening visit and before administration of the initial dose of trial drug, as deemed by the 
Investigator or designee. 
8. Understands the study procedures in the ICF and be willing and able to comply with the 
protocol. 
9. Pulse rate between 60 and 100 bpm and a blood pressure between 90 to 140 mmHg 
systolic and 40 to 90 mmHg diastolic at screening and prior to dosing of Period 1. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 21 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
10. Creatine phosphokinase is ≤1.1x ULN; lipase, amylase, ALT, AST, total bilirubin, 
glucose, and aPTT are ≤ULN at screening and check-in of Period 1. 
7.2 
Exclusion Criteria 
Criteria for Exclusion: 
Subjects must not be enrolled in the study if they meet any of the following criteria: 
1. Is mentally or legally incapacitated or has significant emotional problems at the time of 
the screening visit or expected during the conduct of the study. 
2. History or presence of clinically significant endocrine, gastrointestinal (including motility 
disorder and intestinal obstruction), cardiovascular, hematological, hepatic, 
immunological, renal, respiration, genitourinary, major neurological (including stroke and 
chronic seizures), or malignancy, active infectious diseases, ophthalmologic disorders 
other than presbyopia/myopia/hyperopia/astigmatism, or any other clinically significant 
abnormalities or disease in the opinion of the Investigator or designee. 
3. Any history of major surgery, eg, cholecystectomy, intestinal resections, hepatectomy, 
nephrectomy, digestive organ resection that may affect absorption, metabolism or 
excretion of study drug. A history of appendectomy is not exclusionary. 
4. History of any illness that, in the opinion of the Investigator or designee, might confound 
the results of the study or poses an additional risk to the subject by their participation in 
the study. 
5. History or presence of alcoholism or drug abuse within the past 2 years prior to the first 
dosing. 
6. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or 
related compounds. 
7. Positive urine drug or cotinine, or alcohol results at screening or check-in. 
8. Positive results at screening for HIV, HBsAg, or HCV. 
9. Positive COVID-19 results at first check-in. 
10. Currently has an active infection, in the opinion of the Investigator. 
11. QTcF interval is >460 msec or ECG findings are deemed abnormal with clinical 
significance by the Investigator or designee at screening. 
12. Estimated creatinine clearance <90 mL/minute at screening (calculated using the 
Cockcroft-Gault formula). 
13. Unable to refrain from or anticipates the use of any drug, including prescription and 
nonprescription medications, herbal remedies, or vitamin supplements within 28 days 
prior to the first dosing and throughout the study. Acetaminophen (up to 2 g per 24-hour 
period) may be permitted during the study, only after the first dosing, at the discretion of 
the Investigator or designee, as medically indicated. Thyroid hormone replacement 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 22 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
medication may be permitted if the subject has been on the same stable dose for the 
immediate 3 months prior to the first dosing. 
14. Has been on a diet incompatible with the on-study diet, including consumption of 
grapefruit juice and other grapefruit containing products, in the opinion of the Investigator 
or designee, within the 30 days prior to the first dosing and throughout the study. 
15. Donation of blood or significant blood loss within 56 days prior to the first dosing. 
16. Plasma donation within 7 days prior to the first dosing. 
17. Participation in another clinical study within 30 days prior to the first dosing. The 30-day 
window will be derived from the date of the last blood collection or dosing, whichever is 
later, in the previous study to Day 1 of Period 1 of the current study. 
7.3 
Excluded Medications, Supplements, Dietary Products  
Concomitant medications will be prohibited as listed in the exclusion criteria in Section 7.2. 
Acetaminophen (up to 2 g per 24-hour period) may be permitted during the study, only after the 
first dosing, at the discretion of the Investigator or designee, as medically indicated. Thyroid 
hormone replacement medication may be permitted if the subject has been on the same stable 
dose for the immediate 3 months prior to the first dosing. 
If deviations occur, the Investigator or designee, in consultation with the Sponsor if needed, will 
decide on a case by case basis whether the subject may continue participation in the study. 
All medications taken by subjects during the course of the study will be recorded. 
Use of excluded agents (prescription or non-prescription) or dietary products is outlined in 
Table 7.a. 
Table 7.a 
Excluded Medications, Supplements, and Dietary Products 
Category 
Between Screening and First Dosing 
(Days -28 to predose [Day 1]) 
After First Dosing (Day 1 of 
Period 1) to Follow-Up  
Alcohol 
Prohibited from 48 hours prior to dosing in 
each period 
Prohibited from dosing in each 
period until the last PK sample 
collection of that period. 
Xanthine and/or caffeine 
Prohibited from 24 hours prior to dosing in 
each period a 
Prohibited from dosing in each 
period until the last PK sample 
collection of that period. 
Grapefruit juice and other 
grapefruit containing 
products 
Prohibited from within 30 days prior to dosing 
in Period 1 
Prohibited from dosing in 
Period 1 and throughout the 
study. 
Medications  
See Sections 7.1 and 7.2 
See Sections 7.1 and 7.2 
Nicotine- and tobacco-
containing and/or 
cannabis products 
Prohibited from 3 months prior to dosing in 
Period 1 
Prohibited from first dosing in 
Period 1 and throughout the 
study. 
(a) small amounts of caffeine derived from normal foodstuffs e.g., 250 mL/8 oz./1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 23 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
considered a deviation to this restriction. 
7.4 
Diet, Fluid, Activity  
7.4.1 
Diet and Fluid 
Water (except water provided with each dosing) will be restricted 1 hour prior to and 1 hour after 
each study drug administration, but will be allowed ad libitum at all other times. Other fluids 
may be given as part of meals and snacks but will be restricted at all other times throughout the 
confinement period. 
Subjects will fast overnight for at least 10 hours prior to each study drug administration. Subjects 
will continue the fast for at least 4 hours postdose. 
When confined, standard meals and snacks will be provided at appropriate times, except when 
subjects are required to fast. When confined in the CRU, subjects will be required to fast from all 
food and drink except water between meals and snacks. 
Each meal and/or snack served at the CRU will be standardized and will be similar in caloric 
content and composition and will be taken at approximately the same time in each period. 
7.4.2 
Activity 
Subjects will remain ambulatory or seated upright for the first 4 hours postdose, except when 
subjects are supine or semi-recumbent for study procedures.  
However, should AEs occur at any time, subjects may be placed in an appropriate position or 
will be permitted to lie down on their right side. 
Subjects will be instructed to refrain from strenuous physical activity which could cause muscle 
aches or injury, including contact sports at any time from screening until completion of the 
study. 
Subjects will also be advised to avoid prolonged exposure to natural or artificial sunlight (e.g., 
tanning beds, ultraviolet A/B treatment) at any time starting from check-in for Period 1 until 
completion of the study. Subjects will be advised to wear protective clothing and sunglasses 
when they are in the sun, and use sunscreen with a high protection factor (Sun Protection Factor 
30 and above). 
7.5 
Criteria for Discontinuation or Withdrawal of a Subject 
Subjects are free to withdraw from the study at any time for any reason.  
In addition, subjects may be withdrawn from the study by the Investigator or designee for the 
following reasons: 
• AEs (note that dosing and enrollment will be suspended as per the stopping criterion outlined 
in Section 6.3). 
• A positive pregnancy test for females.* 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 24 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• Positive urine drug or alcohol results. 
• Difficulties in blood collection. 
*This study includes females of non-childbearing potential. In the unlikely event of a female 
becoming pregnant during this study, the female will be withdrawn and will be followed up as 
detailed in Appendix D. 
A subject may be withdrawn by the Investigator (or designee) or the Sponsor if enrollment into 
the study is inappropriate, the study plan is violated, or for administrative and/or other safety 
reasons. 
If a subject is withdrawn prior to study completion, efforts should be made to perform all 
procedures scheduled for early termination as outlined in the Section 3.0, Schedule of Study 
Procedures. 
7.6 
Procedures for Discontinuation or Withdrawal of a Subject 
The Investigator may discontinue a subject’s study participation at any time during the study 
when the subject meets the study termination criteria described in Section 7.5. In addition, a 
subject may discontinue his or her participation without giving a reason at any time during the 
study. Should a subject’s participation be discontinued, the primary criterion for termination 
must be recorded by the Investigator. In addition, efforts should be made to perform all 
procedures scheduled for the end-of-study or early termination as described in Section 3.0. 
7.7 
Subject Replacement 
Replacement of discontinued or withdrawn subjects due to any reason will be assessed on a case 
by case basis by the Sponsor and Investigator to ensure a minimum of 8 PK-evaluable subjects 
complete the study.  
8.0 
CLINICAL STUDY MATERIAL MANAGEMENT 
8.1 
Clinical Study Drug  
Brigatinib will be supplied by the Sponsor and administered as a 90 mg oral solution dose 
(Treatment A, test formulation) and as a 90 mg immediate-release tablet dose (Treatment B, 
reference formulation [ALUNBRIG®]). 
8.1.1 
Clinical Study Drug Labeling 
Study drug containers will be affixed with a clinical label in accordance with local regulatory 
requirements. 
The pharmacy at the CRU will provide each dose in individual unit dose containers for each 
subject. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 25 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
8.1.2 
Clinical Study Drug Inventory and Storage 
The same lot number for each formulation will be used throughout the study. The lot numbers 
and expiration dates (where available) of the study drugs supplied will be recorded in the final 
report. Study drugs will be stored according to the product label provided with the product. 
Records will be made of the receipt, preparation, dispensing, and final disposition of the study 
drugs supplied. 
8.1.3 
Clinical Study Drug Blinding 
This is an open-label study. 
8.1.4 
Randomization Code Creation and Storage  
A computerized randomization scheme will be created by a Celerion statistician. 
A Celerion biostatistician will create a randomization schedule with a SAS program that includes 
a block size of 2 which randomly assigns each subject to a treatment group of A or B. 
8.1.5 
Clinical Study Blind Maintenance/Unblinding Procedure 
Not applicable.  
8.1.6 
Accountability and Destruction of Sponsor-Supplied Drugs 
Records will be made of the receipt and dispensing of the study drugs supplied. At the 
conclusion of the study, any unused brigatinib will be retained by Celerion, returned to the 
Sponsor or designee, or destroyed, as per Sponsor instructions. If no supplies remain, this fact 
will be documented in the pharmacy product accountability records. 
9.0 
STUDY PROCEDURES 
9.1 
Administrative Procedures 
9.1.1 
Informed Consent Procedure 
The purpose of the study, the procedures to be carried out and the potential hazards will be 
described to the subjects in non-technical terms. Subjects will be required to read, sign, and date 
an ICF summarizing the discussion prior to screening, and will be assured that they may 
withdraw from the study at any time without jeopardizing their medical care. 
Subjects will be given a copy of their signed and dated ICF. 
9.1.1.1 
Assignment of Screening and Randomization Numbers  
Each subject will be assigned a unique identification number upon screening. Subjects who 
complete the study screening assessments and meet all the eligibility criteria will be assigned a 
randomization number at the time of dosing, different from the screening number. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 26 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
If replacement subjects are used, the replacement subject number will be 100 more than the 
original (eg, Subject No. 101 will replace Subject No. 1). 
9.1.1.2 
Study Drug Assignment 
All subjects will receive the treatments as detailed in Section 9.2.7. 
9.1.2 
Inclusion and Exclusion  
Please refer to Section 7.1 and Section 7.2. 
9.1.3 
Medical History/Demography 
Medical history and demographic data, including name, sex, age, race, ethnicity, and history of 
tobacco use will be recorded. 
9.1.4 
Concomitant Medications 
Concomitant medications will be prohibited as listed in Section 7.3. All medications taken by 
subjects during the course of the study will be recorded. 
9.2 
Clinical Procedures and Assessments 
The Schedule of Study Procedures (Section 3.0) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. Additional 
evaluations/testing may be deemed necessary by the Investigator or designee and/or the Sponsor 
for reasons related to subject safety. 
For this study, collection of blood for brigatinib PK is the critical parameter and needs to be 
collected as close to the exact time point as possible. All other procedures should be completed 
as close to the prescribed/scheduled time as possible, but can be performed prior to or after the 
prescribed/scheduled time. When ECG coincides with other assessments, the sequence of 
procedures will be safety ECG, vital signs assessment, and then the safety laboratory blood draw. 
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence 
over all routine scheduled procedures. 
9.2.1 
Full Physical Examination 
A full physical examination will be performed as outlined in the Schedule of Study Procedures 
(Section 3.0). Symptom-driven physical examinations may be performed at other times, if 
deemed necessary by the Investigator or designee. 
9.2.2 
Height and Weight 
Body height (cm) and weight (kg) will be reported as outlined in the Schedule of Study 
Procedures (Section 3.0). 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 27 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
9.2.3 
BMI 
BMI will be calculated based on the height and weight measured at screening. 
9.2.4 
Vital Signs 
Single measurements of temperature, respiratory rate, blood pressure and pulse rate, will be 
measured as outlined in the Schedule of Study Procedures (Section 3.0). Additional vital signs 
may be taken at any other times, if deemed necessary. 
Vital sign measurements will be performed with subjects rested in a semi-recumbent position for 
at least 5 minutes before the measurements are acquired, except when they are supine because of 
study procedures and/or AEs (eg, nausea, dizziness) or if deemed necessary by the Investigator 
or designee. 
Vital signs will be measured within 24 hours prior to Day 1 dosing of each period for the predose 
time point. When scheduled postdose, vital signs will be performed within approximately 
15 minutes of the scheduled time point.  
9.2.5 
12-Lead ECG 
Single 12-lead ECGs will be performed as outlined in the Schedule of Study Procedures 
(Section 3.0). Additional ECGs may be taken at any other times, if deemed necessary by the 
Investigator or designee. 
ECGs will be performed with subjects in a supine position (following a 5-minute rest, 
minimum). All ECG tracings will be reviewed by the Investigator or designee. 
ECGs will be measured within 24 hours prior to Day 1 dosing of each period for the predose 
time point. When scheduled postdose, ECGs will be performed within approximately 20 minutes 
of the scheduled time point. 
9.2.6 
Palatability Assessment 
Subjects will be asked to complete a questionnaire for assessment of palatability of the oral 
solution formulation. Palatability assessments, following Treatment A (oral solution) only, will 
be performed as outlined in the Schedule of Study Procedures (Section 3.0).  
9.2.7 
Study Drug Administration 
Brigatinib formulations will be provided as described in Section 8.1. 
The pharmacy at the CRU will provide each dose in individual unit dose containers for each 
subject, according to the randomization schedule.  
Treatments will be administered as follows: 
Oral Solution Administration (Treatment A, test): following an overnight fast of at least 
10 hours, subjects receiving Treatment A will receive a 90 mg oral solution dose of brigatinib 
(ie, 9 mL of the 10 mg/mL solution) immediately followed by approximately 240 mL (8 fluid 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 28 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
ounces) of water. No food will be allowed for at least 4 hours postdose. Water is allowed as 
desired except for one hour before and one hour after drug administration, except for water at 
dosing. 
Tablet Administration (Treatment B, reference): following an overnight fast of at least 10 hours, 
subjects receiving Treatment B will receive a 90 mg tablet dose of brigatinib (ie, one 90 mg 
tablet) with approximately 240 mL (8 fluid ounces) of water. No food will be allowed for at least 
4 hours postdose. Water is allowed as desired except for one hour before and one hour after drug 
administration, except for water at dosing. 
Subjects will be instructed not to crush, split, or chew the brigatinib tablets. 
The date and exact clock time of dosing will be recorded. 
Hour 0 will be set as the dosing time of tablet and relative to the start of dosing for the oral 
solution. 
9.2.8 
AE Monitoring 
Subjects will be monitored throughout the study for adverse reactions to the study drugs and/or 
procedures as described in Section 3.0. 
9.2.9 
Laboratory Procedures and Assessments 
All tests listed below will be performed as outlined in the Schedule of Study Procedures 
(Section 3.0). In addition, laboratory safety tests may be performed at various unscheduled time 
points, if deemed necessary by the Investigator or designee. 
9.2.9.1 
Clinical Laboratory Tests 
Hematology 
Hematology will consist of the following tests: 
Hemoglobin 
Red blood cell count 
Hematocrit  
Platelet count 
Total and differential leukocyte count 
 
 
Coagulation  
Coagulation will consist of the following tests: 
Prothrombin time/ International normalized ratio (INR) 
aPTT 
 
Chemistry 
Serum chemistry tests will be performed after at least an 8-hour fast with the exception of the 
Hour 8 postdose laboratory assessment on Day 1; however, in case of dropouts or rechecks, 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 29 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
subjects may not have fasted for 8 hours prior to when the serum chemistry sample is being 
taken. 
Chemistry evaluations will consist of the following standard chemistry panel: 
Amylase 
Albumin 
Lipase 
Sodium 
Blood Urea Nitrogen 
Potassium 
Bilirubin (total and direct) 
Chloride 
Alkaline phosphatase 
Glucose  
AST 
Creatinine * 
Total Protein 
Lactate dehydrogenase 
Phosphorous 
Testosterone (males only) 
ALT 
Magnesium 
Calcium 
Creatine phosphokinase 
Insulin 
 
* At screening, creatinine clearance will be calculated using the Cockcroft-Gault formula. 
Urinalysis  
Urinalysis will consist of the following tests: 
pH 
Bilirubin 
Specific gravity 
Blood * 
Protein * 
Nitrite * 
Glucose 
Urobilinogen 
Ketones 
Leukocyte esterase * 
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red 
blood cells, white blood cells, bacteria, casts, and epithelial cells) will be performed. 
9.2.9.1.1 
Other  
HIV test 
Urine drug screen 
Opiates (includes morphine, heroin (diacetylmorphine), 
codeine, 6-acetylmorphine, dihydrocodeine, hydrocodone, 
thebaine, and hydromorphone) 
Opioids (includes methadone, oxycodone, and fentanyl) 
Amphetamines 
Barbiturates 
Benzodiazepines 
Cocaine 
Cannabinoids 
HBsAg 
HCV (if antibody positive, confirm RNA negative) 
Urine alcohol screen 
Serum pregnancy test (females only) 
FSH (postmenopausal females only) 
Urine cotinine 
COVID-19 screen  
 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 30 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
9.3 
PK Samples 
Instructions for sample collection, processing, and shipping will be provided in separate 
documents. The date and exact clock time of each PK sample collection will be recorded. 
Primary specimen collection parameters are provided in Table 9.a. 
Table 9.a: 
Primary Specimen Collections 
Specimen Name 
Primary Specimen 
Description of Intended Use 
Sample Collection 
Plasma sample for PK 
Plasma 
Plasma sample for brigatinib 
PK analysis 
Mandatory 
 
9.3.1 
PK Measurements  
Samples from all subjects will be assayed even if the subjects do not complete the study. 
Samples for determination of plasma concentrations of brigatinib will be analyzed using a 
validated bioanalytical method. 
PK parameters of brigatinib will be calculated from the individual concentration-time profiles 
from all evaluable subjects using noncompartmental analysis methods. Actual sampling times, 
rather than scheduled sampling times, will be used in all computations involving sampling times.  
9.3.1.1 
Plasma PK Measurements 
The following PK parameters will be calculated from plasma concentrations of brigatinib, as 
appropriate: 
AUClast: 
Area under the plasma concentration-time profile, from time 0 to the 
time of the last quantifiable concentration. 
AUC: 
Area under the plasma concentration-time profile, from time 0 to infinity 
calculated using the observed value of the last quantifiable concentration. 
AUC%extrap: 
Area under the curve from the last quantifiable concentration to infinity, 
expressed as a percentage of AUC. 
CL/F: 
Apparent clearance after extravascular administration. 
Cmax: 
Maximum observed plasma concentration. 
tmax: 
Time of first occurrence of Cmax. 
t½z: 
Terminal disposition phase half-life. 
λz: 
Terminal disposition phase rate constant. 
Vz/F: 
Apparent volume of distribution during the terminal disposition phase 
after extravascular administration. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 31 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
No value for λz, AUC, AUC%extrap, CL/F, Vz/F, or t½z will be reported for cases that do not 
exhibit a terminal log-linear phase in the concentration versus time profile. 
PK parameters will not be calculated for subjects with less than 3 consecutive postdose time 
points with quantifiable concentrations. 
Individual and mean plasma concentration-time profiles (both linear and log-linear) will be 
included in the final report.  
Additional PK parameters may be estimated as appropriate. 
9.3.2 
Biomarker Measurements  
Not applicable. 
9.3.3 
PGx Measurements  
Not applicable. 
9.3.4 
Confinement 
Subjects will be housed on Day -1 of each period, at the time indicated by the CRU, until after 
the 72-hour blood draw and/or study procedures. Subjects will return for dosing and/or study 
procedures as outlined in the Schedule of Study Procedures (Section 3.0).  
At all times, a subject may be required to remain at the CRU for longer at the discretion of the 
Investigator or designee. 
As per site preference, subjects may be confined throughout the study (i.e., washout period 
and/or return visits). 
 
10.0 
ADVERSE EVENTS 
10.1 
Definitions and Elements of AEs 
An AE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed ICF to participate in a study; it does not necessarily have to have a causal relationship 
with the treatment. 
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, 
whether or not it is considered related to the drug. 
An untoward finding generally may: 
• Indicate a new diagnosis or unexpected worsening of a preexisting condition. (Intermittent 
events for pre-existing conditions or underlying disease should not be considered AEs.) 
• Necessitate therapeutic intervention. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 32 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• Require an invasive diagnostic procedure. 
• Require discontinuation or a change in dose of study medication or a concomitant 
medication. 
• Be considered unfavorable by the Investigator for any reason. 
Diagnoses versus signs and symptoms: 
• Each event should be recorded to represent a single diagnosis. Accompanying signs 
(including abnormal laboratory values or ECG findings) or symptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be 
recorded appropriately as an AE(s). 
Laboratory values and ECG findings: 
• Changes in laboratory values or ECG parameters maybe considered AEs if they are judged to 
be clinically significant (ie, if some action or intervention is required or if the Investigator 
judges the change to be beyond the range of normal physiologic fluctuation). A laboratory 
re-test and/or continued monitoring of an abnormal value are not considered an intervention. 
In addition, repeated or additional noninvasive testing for verification, evaluation or 
monitoring of an abnormality is not considered an intervention. 
• If abnormal laboratory values or ECG findings are the result of pathology for which there is 
an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as an AE. 
Pre-existing conditions: 
• A pre-existing condition (present at the time of signing of informed consent) is considered a 
concurrent medical history condition and should NOT be recorded as an AE. A baseline 
evaluation (eg, laboratory test, ECG, X-ray, etc) should NOT be recorded as an AE unless 
related to a study procedure. However, if the subject experiences a worsening or 
complication of such a concurrent medical history condition, the worsening or complication 
should be recorded appropriately as an AE (worsening or complication occurs after informed 
consent is signed). Investigators should ensure that the event term recorded captures the 
change in the condition (eg, “worsening of…”). 
• If a subject has a pre-existing episodic condition, any occurrence of an episode should only 
be captured as an AE if the episodes become more frequent, serious, or severe in nature, that 
is, Investigators should ensure that the AE term recorded captures the change from Baseline 
in the condition (eg “worsening of…”). 
• If a subject has a concurrent condition, worsening of the condition should only be captured as 
an AE if occurring to a greater extent to that which would be expected. Again, Investigators 
should ensure that the AE term recorded captures the change in the condition (eg, “worsening 
of…”). 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 33 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Worsening of AEs: 
• If the subject experiences a worsening or complication of an AE after the first administration 
of study medication or after any change in study medication, the worsening or complication 
should be recorded as a new AE. Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”). 
Changes in severity of AEs: 
• If the subject experiences a change in the severity of an AE that is not associated with a 
change in study medication, the event should be captured once with the maximum severity 
recorded. 
Preplanned surgeries or procedures: 
• Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of 
informed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre-existing condition, the worsening 
of the condition should be captured appropriately as an AE. Complications resulting from 
any planned surgery should be reported as AEs. 
Elective surgeries or procedures: 
• Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as AEs but should be documented in the subject’s source documents. 
Complications resulting from an elective surgery should be reported as AEs. 
Overdose: 
• An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by a study subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the Investigator or the reporting physician to 
decide whether a dose is to be considered an overdose, in consultation with the Sponsor. 
• All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the (electronic [e]) case report form (CRF), in order to capture this important safety 
information consistently in the database. AEs associated with an overdose will be 
documented on AE CRF(s) according to Section 10.0. 
• Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Section 10.2.8. 
• In the event of drug overdose, the subject should be treated symptomatically. 
10.1.1 
SAEs 
An SAE is defined as any untoward medical occurrence that at any dose: 
1. Results in DEATH. 
2. Is LIFE THREATENING. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 34 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• The term “life threatening” refers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event that hypothetically might have caused 
death if it were more severe. 
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization. 
4. Results in persistent or significant DISABILITY/INCAPACITY. 
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT. 
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following: 
• May require intervention to prevent items 1 through 5 above. 
• May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization. 
• Includes any event or synonym described in the Takeda Medically Significant AE List 
(Table 10.a). 
Table 10.a: 
Takeda Medically Significant AE List  
Term 
Acute respiratory failure/acute respiratory  
distress syndrome 
Hepatic necrosis 
Acute liver failure 
Torsade de pointes / ventricular fibrillation /  
ventricular tachycardia 
Anaphylactic shock 
Acute renal failure 
Malignant hypertension 
Pulmonary hypertension 
Convulsive seizures 
Pulmonary fibrosis 
Agranulocytosis 
Confirmed or suspected endotoxin shock 
Aplastic anemia 
Confirmed or suspected transmission of infectious agent 
by a medicinal product 
Toxic epidermal necrolysis/ 
Stevens-Johnson syndrome 
 
Neuroleptic malignant syndrome / malignant 
hyperthermia 
Spontaneous abortion / stillbirth and fetal death 
 
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Sections 10.1 and 10.1.1). 
10.1.2 
Special Interest AEs 
AEs of special interest identified from previous studies include the following: early onset 
pulmonary events, later-onset pneumonitis, bradycardia, hypertension, gastrointestinal events, 
elevated creatine phosphokinase, pancreatic enzyme elevation, increased insulin/hyperglycemia 
events, vision impairment events, photosensitivity, and liver enzyme increases. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 35 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
10.2 
AE Procedures 
10.2.1 
Assigning Severity/Intensity of AEs 
The Investigator must categorize the severity of each AE according to the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or 
higher [3]. 
For any term that is not specifically listed in the CTCAE scale, intensity will be assigned a grade 
of one through five using the following CTCAE guidelines: 
Grade 1: Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; 
intervention not indicated 
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living* 
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self-care activities of 
daily living** 
Grade 4: Life-threatening consequences; urgent intervention indicated 
Grade 5: Death related to AE 
*Instrumental activities of daily living (ADL) refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc.  
**Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden 
10.2.2 
Assigning Causality of AEs 
The relationship of each AE to study medication(s) will be assessed using the following 
categories: 
Related: 
An AE that follows a reasonable temporal sequence from administration of a 
drug (including the course after withdrawal of the drug), or for which a 
causal relationship is at least a reasonable possibility, i.e., the relationship 
cannot be ruled out, although factors other than the drug, such as underlying 
diseases, complications, concomitant drugs and concurrent treatments, may 
also be responsible. 
Not Related: 
An AE that does not follow a reasonable temporal sequence from 
administration of a drug and/or that can reasonably be explained by other 
factors, such as underlying diseases, complications, concomitant medications 
and concurrent treatments. 
10.2.3 
Start Date  
The start date of the AE is the date that the first signs/symptoms were noted by the subject and/or 
Investigator. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 36 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
10.2.4 
End Date  
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died. 
10.2.5 
Pattern of Adverse Event (Frequency)  
Episodic AEs (eg, headache) or those which occur repeatedly over a period of consecutive days 
are intermittent. All other events are continuous. 
10.2.6 
Action Taken With Study Treatment 
• Drug withdrawn – a study medication is stopped due to the particular AE (see Section 6.3 for 
study stopping criterion) 
• Dose not changed – the particular AE did not require stopping a study medication. 
• Unknown – only to be used if it has not been possible to determine what action has been 
taken. 
• Not applicable – a study medication was stopped for a reason other than the particular AE 
eg, the study has been terminated, the subject died, dosing with study medication had not yet 
started or dosing with study medication was already stopped before the onset of the AE. 
Recommendations for the management of adverse reactions are provided in the ALUNBRIG® 
Prescribing Information (2022). Discontinuation of brigatinib administration should be 
additionally considered for the following: pulmonary symptoms for interstitial lung 
disease/pneumonitis, severe hypertension, severe visual disturbance, symptomatic bradycardia, 
creatine phosphokinase elevation, pancreatic enzyme elevation, uncontrolled hyperglycaemia, 
and photosensitivity. 
10.2.7 
Outcome  
• Recovered/resolved – subject returned to first assessment status with respect to the AE. 
• Recovering/resolving – the intensity is lowered by one or more stages: the diagnosis has or 
signs/symptoms have almost disappeared; the abnormal laboratory value improved, but has 
not returned to the normal range or to the baseline value; the subject died from a cause other 
than the particular AE with the condition remaining “recovering/resolving.” 
• Not recovered/not resolved – there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosis, signs/symptoms or laboratory value on the last day of the observed 
study period has become worse than when it started; is an irreversible congenital anomaly; 
the subject died from another cause with the particular AE state remaining “Not 
recovered/not resolved.” 
• Recovered/ Resolved with sequelae – the subject recovered from an acute AE but was left 
with permanent/significant impairment (eg, recovered from a cardiovascular accident but 
with some persisting paresis). 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 37 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• Fatal – an AE that is considered as the cause of death. 
• Unknown – the course of the AE cannot be followed up due to hospital change or residence 
change at the end of the subject’s participation in the study. 
10.2.8 
Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal Liver 
Function Tests (LFT) 
10.2.8.1 
Collection Period 
Collection of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal LFTs) will commence at 
the time the subject signs the ICF. Routine collection of AEs will continue until the follow-up 
contact ie, Day 14 (± 2 days) after the last dose of investigational product. For subjects who 
discontinue prior to the administration of study medication, AEs will be followed until the 
subject discontinues study participation.  
10.2.8.2 
Reporting AEs 
At each study visit, the Investigator or designee will assess whether any subjective AEs have 
occurred. A neutral question, such as “How have you been feeling since your last visit?” may be 
asked. Subjects may report AEs occurring at any other time during the study. Subjects 
experiencing an SAE prior to the first exposure to investigational product must be monitored 
until the symptoms subside and any clinically relevant changes in laboratory values have 
returned to Baseline or there is a satisfactory explanation for the change. Nonserious AEs that 
begin prior to the first exposure to investigational product, related or unrelated to the study 
procedure, need not be followed-up for the purposes of the protocol. 
All subjects experiencing AEs, whether considered associated with the use of the study 
medication or not, must be monitored until the symptoms subside and any clinically relevant 
changes in laboratory values have returned to Baseline or until there is a satisfactory explanation 
for the changes observed. All AEs will be documented in the AE page of the CRF, whether or 
not the Investigator concludes that the event is related to the drug treatment. The following 
information will be documented for each event: 
• Event term. 
• Start and end date and time. 
• Pattern of AE (frequency). 
• Severity/Intensity. 
• Causality (Investigator’s opinion of the causal relationship between the event and 
administration of study drug[s]). 
• Action taken with study drug. 
• Outcome of event. 
• Seriousness. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 38 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• Concomitant medication administered and/or procedures performed related to the AE. 
10.2.8.3 
Reporting SAEs 
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below: 
A Takeda SAE form must be completed, in English and signed by the Investigator immediately 
or within 24 hours of first onset or notification of the event. The information should be 
completed as fully as possible but contain, at a minimum: 
• A short description of the event, with event onset date and the reason why the event is 
categorized as serious. 
• Subject identification number. 
• Investigator’s name. 
• Name of the study medication(s). 
• Causality assessment. 
The SAE form should be transmitted within 24 hours to the attention of the contact listed 
beneath: 
Contact Type / Role 
Contact 
Serious adverse event and pregnancy reporting 
Pharmacovigilance 
Takeda Development Center Americas, Inc. 
Email: PVSafetyAmericas@tpna.com 
Fax: 224-554-1052 
 
Any SAE spontaneously reported to the Investigator following the AE collection period should 
be reported to the Sponsor if considered related to study participation. 
Reporting of SAEs that begin before first administration of investigational product will follow 
the same procedure for SAEs occurring on treatment. 
10.2.8.3.1 
SAE Follow-Up 
If information is not available at the time of the first report becomes available at a later date, the 
Investigator should complete a follow-up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the 
addressee, if requested. 
All SAEs should be followed up until resolution or permanent outcome of the event. The 
timelines and procedure for follow-up reports are the same as those for the initial report. 
10.2.8.4 
Reporting Special Interest AEs  
AEs of special interest are presented in Section 10.1.2. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 39 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
10.2.8.5 Close Monitoring and Treatment Discontinuation for Potential Drug-Induced Liver 
Injury (DILI) 
Subjects who develop ALT/AST >3xULN after first dosing should be monitored closely and the 
clinical significance of the elevation should be assessed by the investigator. Close observation 
includes the following: 
• Repeating liver enzyme and serum bilirubin tests two or three times weekly. Frequency of 
retesting can decrease to once a week or less if abnormalities stabilize or the study drug has 
been discontinued and the subject is asymptomatic.  
• Obtaining a more detailed history of symptoms and prior or concurrent diseases.  
• Obtaining a history of concomitant drug use (including nonprescription medications and 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and special 
diets.  
• Ruling out acute viral hepatitis types A, B, C, D, and E; autoimmune or alcoholic hepatitis; 
Nonalcoholic steatohepatitis; hypoxic/ischemic hepatopathy; and biliary tract disease.  
• Obtaining a history of exposure to environmental chemical agents.  
• Obtaining additional tests to evaluate liver function, as appropriate (eg, INR, direct bilirubin).  
• Considering gastroenterology or hepatology consultations.  
If a subject develops any of the following after the first dose, treatment should be discontinued, 
the medical monitor should be contacted immediately, and the subject should be withdrawn from 
the study:  
• ALT or AST >5xULN 
• ALT or AST >3xULN at the end of the minimum 14 days washout period 
• ALT or AST >3xULN and (total bilirubin >2xULN or INR >1.5) 
• ALT or AST >3xULN with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
The above criteria if met will be reported as SAEs. All subjects showing possible DILI should be 
followed until all abnormalities return to normal or to the baseline state. Pertinent elements of the 
case should be captured in the DILI CRF.  
10.2.9 
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities  
The Sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, Investigators and 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC), as applicable, in 
accordance with national regulations in the countries where the study is conducted. Relative to 
the first awareness of the event by/or further provision to the Sponsor or Sponsor’s designee, 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 40 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
SUSARs will be submitted within 7 days for fatal and life-threatening events and 15 days for 
other serious events, unless otherwise required by national regulations. The Sponsor will also 
prepare an expedited report for other safety issues where these might materially alter the current 
benefit-risk assessment of an investigational medicinal product or that would be sufficient to 
consider changes in the investigational medicinal products administration or in the overall 
conduct of the study. The investigational site also will forward a copy of all expedited reports to 
his or her IRB or IEC in accordance with national regulations. 
11.0 
STATISTICAL METHODS 
11.1 
Statistical and Analytical Plans 
Detailed methodology for summary and statistical analyses of the data collected in this study will 
be documented in a statistical analysis plan (SAP). The SAP will be prepared by Celerion and 
agreed upon with the Sponsor. This document may modify the plans outlined in the protocol; 
however, any major modifications of the primary endpoints definition and/or its analysis will 
also be reflected in a protocol amendment. Additional statistical analyses other than those 
described in this section may be performed if deemed appropriate. 
11.1.1 
Analysis Sets 
11.1.1.1 
Safety Set 
All subjects who received at least one dose of the study drug(s) will be included in the safety 
evaluations. 
11.1.1.2 
PK Set 
All subjects who comply sufficiently with the protocol and display an evaluable PK profile (eg, 
exposure to treatment, availability of measurements and absence of major protocol violations) 
will be included in the statistical analyses. 
11.1.2 
Analysis of Demography and Other Baseline Characteristics 
Continuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statistics. Categorical demographic data (ie, gender, race, and 
ethnicity) will also be listed and tabulated. 
11.1.3 
PK Analysis 
Statistical analysis of PK data will be based on the PK analysis data set. Additional details 
related to the PK analyses will be described in a separate analysis plan. 
Plasma PK parameters of brigatinib will be derived using standard noncompartmental analysis 
methods. A linear mixed-effects analysis of variance model will be used for the analysis on the 
ln-transformed brigatinib PK parameters (Cmax, AUClast, and AUC). The model will include 
sequence, treatment, and period as fixed effects. Subject nested within sequence will be included 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 41 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
as a random effect. Each model will include calculation of LSM as well as the difference 
between treatment LSM. Geometric mean ratios and 90% CIs will be calculated using the 
exponentiation of the difference between treatment LSM from the analyses on the ln-transformed 
Cmax, AUClast, and AUC. These ratios will be expressed as a ratio of test treatment (ie, oral 
solution) relative to the reference treatment (ie, tablet). 
11.1.4 
PD Analysis  
Not applicable. 
11.1.5 
Safety Analysis 
All safety data will be populated in the individual CRFs.  
Dosing dates and times will be listed by subject. 
TEAEs will be tabulated. The remaining quantitative safety data as well as the difference to 
baseline, when appropriate, will be summarized using the appropriate descriptive statistics. 
11.1.5.1 
AEs 
AEs will be coded using the most current version of Medical Dictionary for Regulatory 
Activities (MedDRA®) available at Celerion and summarized by treatment for the number of 
subjects reporting the TEAE and the number of TEAEs reported. A by-subject AE data listing 
including verbatim term, coded term, treatment, severity, and relationship to treatment will be 
provided. 
11.1.5.2 
Clinical Laboratory Evaluation 
Clinical laboratory results will be summarized by treatment and point of time of collection and a 
shift table describing out of normal range shifts will be provided. 
11.1.5.3 
Vital Signs 
Vital signs assessments will be summarized by treatment and point of time of collection. 
11.1.5.4 
Other Safety Parameters 
Physical examination findings will be presented in the data listings. 
ECGs will be summarized by treatment and point of time of collection. 
Medical history, and concurrent conditions will be coded using the MedDRA® and concomitant 
medications will be coded using the World Health Organization (WHO) drug dictionary and will 
be listed by subject. 
11.2 
Palatability  
Palatability results for Treatment A only will be presented in the data listings and summarized as 
appropriate. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 42 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
11.3 
Interim Analysis and Criteria for Early Termination 
Not applicable. 
11.4 
Determination of Sample Size 
The sample size calculation was based on the expected 2-sided 90% CIs for the difference in the 
paired, ln-transformed AUC means of brigatinib after administration as an oral solution versus 
an immediate-release tablet. The within-subject %CV for brigatinib AUC was estimated to be 
12% on the basis of data from previous clinical studies conducted in healthy subjects (Studies 
AP26113-15-106 and AP26113-16-110). If the observed GMR for brigatinib AUC after 
administration as an oral solution versus a tablet is 1, with a sample size of 8, the 90% CIs for the 
GMR is expected to be 0.89 to 1.12 on the basis of the variance assumptions. 
It is anticipated that a total of approximately 12 subjects will be enrolled to obtain at least 
8 PK-evaluable subjects. Subjects will be randomized into 2 treatment sequences, as indicated in 
Table 6.a.  
12.0 
QUALITY CONTROL AND QUALITY ASSURANCE 
12.1 
Study-Site Monitoring Visits 
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the CRFs. Source documents are defined as original documents, data, and records. 
The Investigator and study site guarantee access to source documents by the Sponsor or its 
designee and by the IRB or IEC. 
All aspects of the study and its documentation will be subject to review by the Sponsor or the 
Sponsor’s designee, including but not limited to the Investigator’s Binder, study drug, subject 
medical records, informed consent documentation, and review of CRFs and associated source 
documents. It is important that the Investigator and other study personnel are available during the 
monitoring visits and that sufficient time is devoted to the process. 
12.2 
Protocol Deviations 
The Investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will 
require deviation from protocol-specified procedures, the Investigator should consult with the 
Sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action. 
There will be no exemptions (a prospectively approved deviation) from the inclusion or 
exclusion criteria. 
Significant deviations include, but are not limited to, those that involve fraud or misconduct, 
increase the health risk to the subject, or confound interpretation of primary study assessment.  
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 43 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
12.3 
Quality Assurance Audits and Regulatory Agency Inspections 
The study site also may be subject to quality assurance audits by the Sponsor or designees. In 
this circumstance, the Sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by the regulatory agency, the 
Food and Drug Administration (FDA). If the study site is contacted for an inspection by a 
regulatory body, the Sponsor should be notified immediately. The Investigator guarantees access 
for quality assurance auditors to all study documents as described in Section 12.1. 
13.0 
ETHICAL ASPECTS OF THE STUDY 
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the International Conference on Harmonisation (ICH) Harmonised Tripartite 
Guideline for GCP. Each Investigator will conduct the study according to applicable local or 
regional regulatory requirements and align his or her conduct in accordance with the 
“Responsibilities of the Investigator” that are listed in Appendix A. The principles of Helsinki 
are addressed through the protocol and through appendices containing requirements for informed 
consent and Investigator responsibilities. 
13.1 
IRB and/or IEC Approval 
IRBs and IECs must be constituted according to the applicable state and federal/local 
requirements of each participating region. The Sponsor or designee will require documentation 
noting all names and titles of members who make up the respective IRB or IEC. If any member 
of the IRB or IEC has direct participation in this study, written notification regarding his or her 
abstinence from voting must also be obtained. Those Americas sites unwilling to provide names 
and titles of all members due to privacy and conflict of interest concerns should instead provide a 
Federal Wide Assurance Number or comparable number assigned by the Department of Health 
and Human Services. 
The Sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy of the ICF, and, if 
applicable, subject recruitment materials and/or advertisements and other documents required by 
all applicable laws and regulations, must be submitted to a central or local IRB or IEC for 
approval. The IRB’s or IEC’s written approval of the protocol and subject informed consent 
must be obtained and submitted to the Sponsor or designee before commencement of the study 
(ie, before shipment of the Sponsor-supplied drug or study specific screening activity). The IRB 
or IEC approval must refer to the study by exact protocol title, number, and version date; identify 
versions of other documents (eg, ICF) reviewed; and state the approval date. The Sponsor will 
ship drug/notify site once the Sponsor has confirmed the adequacy of site regulatory 
documentation and, when applicable, the Sponsor has received permission from competent 
authority to begin the study. Until the site receives drug/notification no protocol activities, 
including screening, may occur. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 44 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Sites must adhere to all requirements stipulated by their respective IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruitment 
materials intended for viewing by subjects, local safety reporting requirements, reports and 
updates regarding the ongoing review of the study at intervals specified by the respective IRB or 
IEC, and submission of the investigator’s final status report to IRB or IEC. All IRB and IEC 
approvals and relevant documentation for these items must be provided to the Sponsor or its 
designee. 
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and Sponsor. 
13.2 
Subject Information, Informed Consent, and Subject Authorization 
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, subject authorization form (if applicable), and subject 
information sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subject’s personal and personal health information for purposes of conducting 
the study. The ICF and the subject information sheet (if applicable) further explain the nature of 
the study, its objectives, and potential risks and benefits, as well as the date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any time without giving a reason and without prejudice to his or her further medical 
care. 
The Investigator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the subject authorization form. The ICF, subject authorization form (if 
applicable), and subject information sheet (if applicable) must be approved by both the IRB or 
IEC and the Sponsor prior to use. 
The ICF, subject authorization form (if applicable), and subject information sheet (if applicable) 
must be written in a language fully comprehensible to the prospective subject. It is the 
responsibility of the Investigator to explain the detailed elements of the ICF, subject 
authorization form (if applicable), and subject information sheet (if applicable) to the subject. 
Information should be given in both oral and written form whenever possible and in the manner 
deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally acceptable representative may 
provide such consent for the subject in accordance with applicable laws and regulations. 
The subject, or the subject’s legally acceptable representative, must be given ample opportunity 
to: (1) inquire about details of the study, and (2) decide whether or not to participate in the study. 
If the subject, or the subject’s legally acceptable representative, determines he or she will 
participate in the study, then the ICF and subject authorization form (if applicable) must be 
signed and dated by the subject, or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study. The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpoint ink. The Investigator must also sign and date the ICF and subject 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 45 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
authorization (if applicable) at the time of consent and prior to subject entering into the study; 
however, the Sponsor may allow a designee of the Investigator to sign to the extent permitted by 
applicable law. 
Once signed, the original ICF, subject authorization form (if applicable), and subject information 
sheet (if applicable) will be stored in the Investigator’s site file. The Investigator must document 
the date the subject signs the informed consent in the subject’s medical record. Copies of the 
signed and dated ICF, the signed subject authorization form (if applicable), and subject 
information sheet (if applicable) shall be given to the subject. 
All revised ICFs must be reviewed, signed, and dated by relevant subjects or the relevant 
subject’s legally acceptable representative in the same manner as the original informed consent. 
The date the revised consent was obtained should be recorded in the subject’s medical record, 
and the subject should receive a copy of the revised signed and dated ICF. 
13.3 
Subject Confidentiality 
The Sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the Sponsor’s clinical study database or documentation via a unique identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or 
date of birth, and subject initials may be used to verify the subject and accuracy of the subject’s 
unique identification number. 
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator to permit its monitor or designee’s monitor, representatives 
from any regulatory authority (eg, FDA), the Sponsor’s designated auditors, and the appropriate 
IRBs and IECs to review the subject’s original medical records (source data or documents), 
including, but not limited to, laboratory test result reports, ECG reports, admission and discharge 
summaries for hospital admissions occurring during a subject’s study participation, and autopsy 
reports. Access to a subject’s original medical records requires the specific authorization of the 
subject as part of the informed consent process (see Section 13.2). 
Copies of any subject source documents that are provided to the Sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s CRF). 
13.4 
Publication, Disclosure, and Clinical Study Registration Policy 
13.4.1 
Publication and Disclosure 
The Investigator is obliged to provide the Sponsor with complete test results and all data derived 
by the Investigator from the study. During and after the study, only the Sponsor may make study 
information available to other study Investigators or to regulatory agencies, except as required by 
law or regulation. Except as otherwise allowable in the clinical study site agreement, any public 
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of the Sponsor. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 46 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
The Sponsor may publish any data and information from the study (including data and 
information generated by the investigator) without the consent of the Investigator. Manuscript 
authorship for any peer-reviewed publication will appropriately reflect contributions to the 
production and review of the document. All publications and presentations must be prepared in 
accordance with this section and the Clinical Study Site Agreement. In the event of any 
discrepancy between the protocol and the Clinical Study Site Agreement, the Clinical Study Site 
Agreement will prevail. 
13.4.2 
Clinical Study Registration  
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, Takeda will, at a minimum register all 
interventional clinical trials it Sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly accessible websites before start of study, as defined in Takeda Policy/Standard. Takeda 
contact information, along with Investigator’s city, state (for Americas Investigators), country, 
and recruiting status will be registered and available for public viewing.  
For some registries, Takeda will assist callers in locating study sites closest to their homes by 
providing the Investigator name, address, and phone number to the callers requesting trial 
information. Once subjects receive Investigator contact information, they may call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of trial enrollment, they should be referred to the Sponsor. 
Any Investigator who objects to the Sponsor providing this information to callers must provide 
the Sponsor with a written notice requesting that their information not be listed on the registry 
site. 
13.4.3 
Clinical Study Results Disclosure  
Takeda will post the results of clinical studies on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulations. 
13.5 
Insurance and Compensation for Injury 
Each subject in the study must be insured in accordance with the regulations applicable to the 
site where the subject is participating. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will obtain clinical study insurance against the risk of injury to study 
subjects. Refer to the study site agreement regarding the Sponsor’s policy on subject 
compensation and treatment for injury. If the Investigator has questions regarding this policy, he 
or she should contact the Sponsor or Sponsor’s designee. 
 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 47 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
14.0 
ADMINISTRATIVE AND REFERENCE INFORMATION 
14.1 
Administrative Information 
14.1.1 
Study Contact Information  
Contact Type / Role 
Contact 
Serious adverse event and pregnancy reporting 
Pharmacovigilance 
Takeda Development Center Americas, Inc. 
Email: PVSafetyAmericas@tpna.com 
Fax: 224-554-1052 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 48 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
14.1.2 
INVESTIGATOR AGREEMENT  
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, 
package insert and any other product information provided by the Sponsor. I agree to conduct 
this study in accordance with the requirements of this protocol and also to protect the rights, 
safety, privacy, and well-being of study subjects in accordance with the following: 
• The ethical principles that have their origin in the Declaration of Helsinki. 
• International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated 
Guideline. 
• All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations. 
• Regulatory requirements for reporting serious adverse events defined in Section 10.2.9 of this 
protocol. 
• Terms outlined in the study site agreement. 
• Responsibilities of the Investigator (Appendix A). 
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix C of this protocol. 
Signature of Investigator 
Date 
Investigator Name (print or type) 
Investigator’s Title 
Location of Facility (City, State/Provence) 
Location of Facility (Country) 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 49 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
14.1.3 
Study-Related Responsibilities  
The Sponsor will perform all study-related activities with the exception of those identified in the 
Study-Related Responsibilities template. The vendors identified for specific study-related 
activities will perform these activities in full or in partnership with the Sponsor. 
14.1.4 
List of Abbreviations 
ADL 
Activities of Daily Living 
AE 
Adverse event 
ALK 
Anaplastic lymphoma kinase 
ALT 
Alanine aminotransferase 
aPTT 
Activated partial thromboplastin time 
AST 
Aspartate transaminase 
AUC 
Area under the plasma concentration-time profile 
AUC 
Area under the plasma concentration-time profile from time 0 to infinity 
AUC%extrap 
Percent of AUC extrapolated 
AUClast 
Area under the plasma concentration-time profile from time 0 to the time of the last 
quantifiable concentration 
BMI 
Body mass index 
bpm 
Beats per minute 
CFR 
Code of Federal Regulations 
CI 
Confidence interval 
CL/F 
Apparent clearance after extravascular administration 
Cm 
Centimeter 
Cmax 
Maximum observed plasma concentration  
COVID-19 
Coronavirus Disease-2019 
CRF 
Case report form 
CRU 
Clinical Research Unit 
CTCAE 
Common Terminology Criteria for Adverse Events 
%CV 
Percent coefficient of variation 
CYP 
Cytochrome P450 
DILI 
Drug-induced liver injury 
ECG 
Electrocardiogram 
FDA 
Food and Drug Administration 
FSH 
Follicle stimulating hormone 
g 
Gram 
GCP 
Good Clinical Practice 
GMR 
Geometric mean ratio 
h 
Hour 
HBsAg 
Hepatitis B surface antigen 
hCG 
Human chorionic gonadotropin 
HCV 
Hepatitis C virus  
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 50 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
IU 
International units 
kg 
Kilogram 
L 
Liter 
LFT 
Liver function tests 
ln 
Natural log 
LSM 
Least squares mean 
m2 
Meters squared 
MedDRA® 
Medical Dictionary for Regulatory Activities® 
mg 
Milligram 
MHRA 
Medicines and Healthcare products Regulatory Agency 
mL 
Milliliter 
mmHg 
Millimeter of mercury 
msec 
Millisecond 
NCI 
National Cancer Institute  
NSCLC 
Non-small cell lung cancer 
PK 
Pharmacokinetic(s) 
PMDA 
Pharmaceuticals and Medical Devices Agency 
QD 
Once daily 
QTcF 
An electrocardiographic finding in which the QT interval corrected for heart rate 
using Fridericia's formula 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SUSAR 
Suspected unexpected serious adverse reaction 
t½z 
Terminal disposition phase half-life 
TEAE 
Treatment-emergent adverse event 
tmax 
Time of first occurrence of maximum observed plasma concentration 
ULN 
Upper limit of normal 
USPI 
United States Prescribing Information 
Vz/F 
Apparent volume of distribution during the terminal disposition phase after 
extravascular administration 
WHO 
World Health Organization 
λz 
Terminal disposition phase rate constant 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 51 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
15.0 
DATA HANDLING AND RECORDKEEPING 
The full details of procedures for data handling will be documented in the Data Management 
Plan. AEs, medical history, and concurrent conditions will be coded using the MedDRA. Drugs 
will be coded using the WHO Drug Dictionary. 
15.1 
CRFs (Electronic and Paper) 
The Sponsor or its designee will supply investigative sites with access to CRFs. The Sponsor will 
make arrangements to train appropriate site staff in the use of the CRF. These forms are used to 
transmit the information collected in the performance of this study to the Sponsor and regulatory 
authorities. CRFs must be completed in English. Data are transcribed directly onto CRFs. 
After completion of the entry process, computer logic checks will be run to identify items, such 
as inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.  
Corrections are recorded in an audit trail that captures the old information, the new information, 
identification of the person making the correction, the date the correction was made, and the 
reason for change. Reasons for significant corrections should additionally be included.  
The Principal Investigator must review the CRFs for completeness and accuracy and must sign 
and date the appropriate CRFs as indicated. Furthermore, the Investigator must retain full 
responsibility for the accuracy and authenticity of all data entered on the CRFs. 
After the lock of the clinical study database, any change of, modification of, or addition to the 
data on the CRFs should be made by the Investigator with use of change and modification 
records of the CRFs. The Principal Investigator must review the data change for completeness 
and accuracy, and must sign and date.  
CRFs will be reviewed for completeness and acceptability at the study site during periodic visits 
by study monitors. The Sponsor or its designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the CRFs. The completed CRFs 
are the sole property of the Sponsor and should not be made available in any form to third 
parties, except for authorized representatives of appropriate governmental health or regulatory 
authorities, without written permission of the Sponsor. 
15.2 
Record Retention 
The Investigator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal health information (if separate from the informed consent forms), electronic copy of 
CRFs, including the audit trail, and detailed records of drug disposition to enable evaluations or 
audits from regulatory authorities, the Sponsor or its designees. Any source documentation 
printed on degradable thermal sensitive paper should be photocopied by the site and filed with 
the original in the subject’s chart to ensure long-term legibility. Furthermore, ICH E6 Section 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 52 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
4.9.5 requires the Investigator to retain essential documents specified in ICH E6 (Section 8) until 
at least 2 years after the last approval of a marketing application for a specified drug indication 
being investigated or, if an application is not approved, until at least 2 years after the 
investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 Section 
4.9.5 states that the study records should be retained until an amount of time specified by 
applicable regulatory requirements or for a time specified in the Clinical Study Site Agreement 
between the Investigator and Sponsor. 
Refer to the Clinical Study Site Agreement for the Sponsor’s requirements on record retention. 
The Investigator and the head of the institution should contact and receive written approval from 
the Sponsor before disposing of any such documents. 
16.0 
REFERENCES 
1. Brigatinib (AP26113), Investigators Brochures, Edition 9.0, 12 Jun 2019. 
2. ALUNBRIG® (Brigatinib). Prescribing Information. Revised 02/2022. Available at: 
https://www.alunbrig.com/assets/pi.pdf 
3. National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0, Nov 2017. Available at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Qu
ick_Reference_8.5x11.pdf 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 53 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
17.0 
APPENDICES 
Appendix A Responsibilities of the Investigator 
Clinical research studies sponsored by the Sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. The responsibilities imposed on Investigators by the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572), which must be completed and 
signed before the Investigator may participate in this study. 
The Investigator agrees to assume the following responsibilities by signing a Form FDA 1572: 
1. Conduct the study in accordance with the protocol. 
2. Personally conduct or supervise the staff that will assist in the protocol. 
3. If the investigator/institution retains the services of any individual or party to perform 
trial-related duties and functions, the investigator/institution should ensure that this 
individual or party is qualified to perform those trial-related duties and functions and 
should implement procedures to ensure the integrity of the trial-related duties and 
functions performed and any data generated. 
4. Ensure that study related procedures, including study specific (nonroutine/nonstandard 
panel) screening assessments are NOT performed on potential subjects, prior to the receipt 
of written approval from relevant governing bodies/authorities. 
5. Ensure that all colleagues and employees assisting in the conduct of the study are 
informed of these obligations. 
6. Secure prior approval of the study and any changes by an appropriate IRB/IEC that 
conform to 21 Code of federal Regulations (CFR) Part 56, ICH, and local regulatory 
requirements. 
7. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and 
approval of the protocol. Promptly report to the IRB/IEC all changes in research activity 
and all anticipated risks to subjects. Make at least yearly reports on the progress of the 
study to the IRB/IEC, and issue a final report within 3 months of study completion. 
8. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and 
local regulations, are met. 
9. Obtain valid informed consent from each subject who participates in the study, and 
document the date of consent in the subject’s medical chart. Valid informed consent is the 
most current version approved by the IRB/IEC. Each informed consent form should 
contain a subject authorization section that describes the uses and disclosures of a 
subject’s personal information (including personal health information) that will take place 
in connection with the study. If an informed consent form does not include such a subject 
authorization, then the Investigator must obtain a separate subject authorization form from 
each subject or the subject’s legally acceptable representative. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 54 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
10. Prepare and maintain adequate case histories of all persons entered into the study, 
including CRFs, hospital records, laboratory results, etc, and maintain these data for a 
minimum of 2 years following notification by the Sponsor that all investigations have 
been discontinued or that the regulatory authority has approved the marketing application. 
The Investigator should contact and receive written approval from the Sponsor before 
disposing of any such documents. 
11. Allow possible inspection and copying by the regulatory authority of GCP-specified 
essential documents. 
12. Maintain current records of the receipt, administration, and disposition of 
Sponsor-supplied drugs, and return all unused Sponsor-supplied drugs to the Sponsor.  
13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the 
Sponsor within 24 hours. 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 55 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Appendix B Elements of the Subject Informed Consent 
In seeking informed consent, the following information shall be provided to each subject: 
1. A statement that the study involves research. 
2. An explanation of the purposes of the research. 
3. The expected duration of the subject’s participation. 
4. A description of the procedures to be followed, including invasive procedures. 
5. The identification of any procedures that are experimental. 
6. The estimated number of subjects involved in the study. 
7. A description of the subject’s responsibilities. 
8. A description of the conduct of the study. 
9. A statement describing the treatment(s) and the probability for random assignment to each 
treatment. 
10. A description of the possible side effects of the treatment that the subject may receive. 
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant. 
12. A description of any benefits to the subject or to others that reasonably may be expected 
from the research. When there is no intended clinical benefit to the subject, the subject 
should be made aware of this. 
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that 
might be advantageous to the subject and their important potential risks and benefits. 
14. A statement describing the extent to which confidentiality of records identifying the 
subject will be maintained, and a note of the possibility that regulatory agencies, 
auditor(s), IRB/IEC, and the monitor may inspect the records. By signing a written ICF, 
the subject or the subject’s legally acceptable representative is authorizing such access. 
15. For research involving more than minimal risk, an explanation as to whether any 
compensation and an explanation as to whether any medical treatments are available if 
injury occurs and, if so, what they consist of or where further information may be 
obtained. 
16. The anticipated prorated payment(s), if any, to the subject for participating in the study. 
17. The anticipated expenses, if any, to the subject for participating in the study. 
18. An explanation of whom to contact for answers to pertinent questions about the research 
(Investigator), subject’s rights, and IRB/IEC and whom to contact in the event of a 
research-related injury to the subject. 
19. A statement that participation is voluntary, that refusal to participate will involve no 
penalty or loss of benefits to which the subject otherwise is entitled, and that the subject or 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 56 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
the subject’s legally acceptable representative may discontinue participation at any time 
without penalty or loss of benefits to which the subject is otherwise entitled. 
20. The consequences of a subject’s decision to withdraw from the research and procedures 
for orderly termination of participation by the subject. 
21. A statement that the subject or the subject’s legally acceptable representative will be 
informed in a timely manner if information becomes available that may be relevant to the 
subject’s willingness to continue participation in the study. 
22. The foreseeable circumstances or reasons under which the subject’s participation in the 
study may be terminated. 
23. A written subject authorization (either contained within the ICF or provided as a separate 
document) describing to the subject the contemplated and permissible uses and disclosures 
of the subject’s personal information (including personal health information) for purposes 
of conducting the study. The subject authorization must contain the following statements 
regarding the uses and disclosures of the subject’s personal information: 
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs; 
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law; 
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safety and effectiveness of the study medication(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies; 
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and 
e) that the subject’s identity will remain confidential in the event that study results are 
published. 
24. Female subjects of non-childbearing potential must have undergone one of the following 
sterilization procedures at least 6 months prior to dosing (hysteroscopic sterilization, 
bilateral tubal ligation, bilateral salpingectomy, hysterectomy, or bilateral oophorectomy); 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 57 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
or be postmenopausal with amenorrhea for at least 1 year prior to dosing and FSH serum 
levels consistent with postmenopausal status.  
25. Male subjects must agree to use a condom with spermicide (as defined in the informed 
consent) from signing the informed consent throughout the duration of the study and for at 
least 3 months after the last dose of study drug (No restrictions are required for a 
vasectomized male provided his bilateral vasectomy procedure has been performed at 
least 1 year prior to the first dosing of study drug. A male who has been vasectomized less 
than 1 year prior to study first dosing must follow the same restrictions as a 
nonvasectomized male). A vasectomized subject may not use vasectomy as his 
primary/only form of contraception if he is unable to provide the surgical documentation 
(refer to Appendix D). 
26. A statement that clinical trial information from this trial will be publicly disclosed in a 
publicly accessible website, such as ClinicalTrials.gov. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 58 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Appendix C Investigator Consent to the Use of Personal Information  
Takeda will collect and retain personal information of Investigator, including his or her name, 
address, and other personally identifiable information. In addition, Investigator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following: 
• Takeda, its affiliates, and licensing partners. 
• Business partners assisting Takeda, its affiliates, and licensing partners. 
• Regulatory agencies and other health authorities. 
• IRBs and IECs. 
Investigator’s personal information may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the following: 
• Assessment of the suitability of Investigator for the study and/or other clinical studies. 
• Management, monitoring, inspection, and audit of the study. 
• Analysis, review, and verification of the study results. 
• Safety reporting and pharmacovigilance relating to the study. 
• Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study. 
• Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies that may 
contain the same chemical compound present in the study medication. 
• Inspections and investigations by regulatory authorities relating to the study. 
• Self-inspection and internal audit within Takeda, its affiliates, and licensing partners. 
• Archiving and audit of study records. 
• Posting investigator site contact information, study details and results on publicly accessible 
clinical trial registries, databases, and websites. 
Investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in Investigator’s 
own country. 
Investigator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above. 
 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 59 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Appendix D Pregnancy and Contraception 
Contraception and Pregnancy Avoidance Procedure 
Male Subjects and Their Female Partners 
Based on findings in male reproductive organs in animals, brigatinib may cause reduced fertility 
in males. From signing of informed consent, throughout the duration of the study, and for at least 
3 months after last dose of study drug, nonsterilized** male subjects who are sexually active 
with a female partner of childbearing potential* must use barrier contraception (eg, condom with 
spermicide). In addition, they must be advised not to donate sperm during this period. Females of 
childbearing potential who are partners of male subjects are also advised to use additional 
contraception as shown in the list containing highly effective/effective contraception below. 
Female Subjects and Their Male Partners 
Definitions and Procedures for Contraception and Pregnancy Avoidance 
The following definitions apply for contraception and pregnancy avoidance procedures. 
* A woman is considered a woman of childbearing potential (WOCBP), i.e. fertile, following 
menarche and until becoming post-menopausal unless permanently sterile. Permanent 
sterilization methods include hysterectomy, and bilateral oophorectomy. A postmenopausal state 
is defined as no menses for 12 months without an alternative medical cause. A high FSH level in 
the postmenopausal range (FSH >40 IU/L) may be used to confirm a post-menopausal state in 
younger women (eg, those <45 year old) or women who are not using hormonal contraception or 
hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single 
FSH measurement is insufficient.  
** Sterilized males should be at least 1 year post-bilateral vasectomy and have confirmed that 
they have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchidectomy. 
The following procedures apply for contraception and pregnancy avoidance. 
1. Highly effective methods of contraception are defined as “those, alone or in combination, 
that result in a low failure rate (ie, less than 1% failure rate per year when used 
consistently and correctly). Females of reproductive potential should be advised to use 
effective non-hormonal contraception during treatment with brigatinib and for at least 
4 months following the final dose of brigatinib. 
In this study, the only acceptable methods of contraception for female participating subjects are:  
• Non-Hormonal Methods:  
– hysteroscopic sterilization,  
– bilateral tubal ligation or bilateral salpingectomy,  
– hysterectomy,  
– bilateral oophorectomy. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 60 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
– postmenopausal with amenorrhea for at least 1 year prior to dosing and FSH serum 
levels consistent with postmenopausal status. 
2. Unacceptable methods of contraception are: 
• Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods). 
• Spermicides only. 
• Withdrawal. 
• No method at all. 
• Use of female and male condoms together. 
• Cap/diaphragm/sponge without spermicide and condom without spermicide. 
• Sexual abstinence is NOT an acceptable method of contraception. 
3. Subjects will be provided with information on highly effective/effective methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they understand the requirements for avoidance of pregnancy, 
donation of ova, and sperm donation during the course of the study and poststudy. 
4. All subjects (male and female) will receive continued guidance with respect to the 
avoidance of pregnancy and sperm and ova donations as part of the study procedures. 
Such guidance should include a reminder of the following: 
a) contraceptive requirements of the study 
b) reasons for use of barrier methods (ie, condom with spermicide) in males with pregnant 
partners 
c) assessment of subject compliance through questions such as 
i. Have you used the contraception consistently and correctly since the last visit? 
ii. Have you forgotten to use contraception since the last visit?  
iii. Are your menses late (even in women with irregular or infrequent menstrual cycles a 
pregnancy test must be performed if the answer is “yes”) 
iv. Is there a chance you or your partner could be pregnant? 
5. In addition to a negative serum human chorionic gonadotropin (hCG) pregnancy test at 
Screening, female subjects must also have a negative serum hCG pregnancy test prior to 
receiving first dose of investigational drug as close as possible and prior to first dose of 
investigational drug, preferably on the same day. 
General Guidance With Respect to the Avoidance of Pregnancy 
Such guidance should include a reminder of the following: 
• contraceptive requirements of the study. 
For non-commercial use only


Brigatinib 
Study No. Brigatinib-1004 
Page 61 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
CONFIDENTIAL 
•
reasons for use of barrier methods (ie, condom with spermicide) in males with pregnant
partners.
•
assessment of subject compliance through questions such as:
–
Have you used the contraception consistently and correctly since the last visit?
–
Have you forgotten to use contraception since the last visit?
–
Are your menses late (even in women with irregular or infrequent menstrual cycles a
pregnancy test must be performed if the answer is “yes”)
–
Is there a chance you could be pregnant?
Pregnancy 
Women of childbearing potential will not be included in this study. 
Any pregnancies in the partner of a male subject during the study or for at least 3 months after 
the last dose, should also be recorded following authorization from the subject’s partner.  
If the female partner of a male subject agrees to the primary care physician being informed, the 
Investigator or designee should notify the primary care physician that the female partner of the 
subject was participating in a clinical study at the time she became pregnant and provide details 
of the study drug the subject received (blinded or unblinded, as applicable). 
After obtaining consent, all pregnancies of female partners of male subjects, in subjects on active 
study drug (including comparator, if applicable) will be followed up to final outcome, using the 
pregnancy form. Pregnancies will remain blinded to the study team. The outcome, including any 
premature termination, must be reported to the sponsor. An evaluation after the birth of the child 
will also be conducted. 
This study includes females of non-childbearing potential. In the unlikely event of a female 
subject becoming pregnant during this study, the pregnancy will also be followed up as detailed 
above. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 62 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
Appendix E Detailed Description of Amendments to Text 
Amendment 01 
Change 1. The verbiage in the criteria for inclusion (#3) (Section 1.0 - STUDY SUMMARY 
and Section 7.1 – Inclusion Criteria) was updated. 
Rationale for the change: Verbiage was updated as per FDA communication under IND 110935 
dated October 27, 2023 to include information regarding duration of ova donation for females:  
Update in strikethrough for text removed and in bold for text added. 
Male or female subjects must agree not to donate sperm or ova from the first dosing until at 
least 3 months and female subjects must agree not to donate ova from the first dosing until 
at least 4 months after the last study drug dosing.  
Change 2. The verbiage in the introduction (Section 4.1 - Background) was updated. 
Rationale for the change: Verbiage was added to include information regarding male fertility 
from previous studies. 
Added the paragraph in bold: 
Testicular toxicity was observed in repeat-dose animal studies. In rats, findings included 
lower weight of testes, seminal vesicles and prostate gland, and testicular tubular 
degeneration; these effects were not reversible during the 2 month recovery period. In 
monkeys, findings included reduced size of testes along with microscopic evidence of 
hypospermatogenesis; these effects were reversible during the recovery period [2]. 
Change 3. Verbiage was added to initiate study suspension in the event of AEs 
(Section 6.3 - Stopping Rules)  
Rationale for the change: Verbiage was updated to include a study stopping criterion as per 
FDA communication under IND 110935 dated October 27, 2023. 
Update in strikethrough for text removed and in bold for text added. 
Not applicable 
Enrollment and dosing will be suspended if Grade ≥3 adverse events (AE) considered at least 
possibly related to the study drug are observed in two participants in a dosing cohort (refer to 
Section 10.2.1 and 10.2.2) after review by the Investigator and the Sponsor. If appropriate, the 
protocol will be amended after safety review. 
Change 4. Verbiage was added for consistency (Section 7.5 – Criteria for Discontinuation or 
Withdrawal of a Subject) 
Rationale for the change: Verbiage was added to include reference to the stopping criterion. 
Update in bold for text added (first bullet). 
In addition, subjects may be withdrawn from the study by the Investigator or designee for the 
following reasons: 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 63 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
• AEs (note that dosing and enrollment will be suspended as per the stopping criterion 
outlined in Section 6.3) 
Change 5. Verbiage was added for consistency (Section 10.2.6– Action Taken With Study 
Treatment 
Rationale for the change: Verbiage was added to include reference to the stopping criterion. 
Update in bold for text added (first bullet). 
• Drug withdrawn – a study medication is stopped due to the particular AE (see Section 6.3 
for study stopping criterion) 
Change 6. The verbiage for #25 (Appendix B – Elements of the Subject Informed Consent) 
was updated 
Rationale for the change: Verbiage was updated for consistency with Inclusion #2:  
Update in strikethrough for text removed and in bold for text added (#25). 
Male subjects must use must agree to use a condom with spermicide (as defined in the informed 
consent) from signing the informed consent throughout the duration of the study and for at least 
3 months after the last dose of study drug. (No restrictions are required for a vasectomized 
male provided his bilateral vasectomy procedure has been performed at least 1 year prior 
to the first dosing of study drug. A male who has been vasectomized less than 1 year prior 
to study first dosing must follow the same restrictions as a nonvasectomized male). A 
vasectomized subject may not use vasectomy as his primary/only form of contraception if 
he is unable to provide the surgical documentation (refer to Appendix D). 
Change 7. The verbiage for describing fertility and contraceptive measures  
(Appendix D - Pregnancy and Contraception) was updated as per FDA communication under 
IND 110935 dated October 27, 2023. 
Rationale for the change: Verbiage was included to provide information on fertility for male 
subjects and for contraceptive measures for females of reproductive potential. 
Update in bold for text added. 
Male Subjects and Their Female Partners 
Based on findings in male reproductive organs in animals, brigatinib may cause reduced 
fertility in males. From signing of informed consent, throughout the duration of the study, and 
for at least 3 months after last dose of study drug, nonsterilized** male subjects who are 
sexually active with a female partner of childbearing potential* must use barrier contraception 
(eg, condom with spermicide). In addition, they must be advised not to donate sperm during 
this period. Females of childbearing potential who are partners of male subjects are also advised 
to use additional contraception as shown in the list containing highly effective/effective 
contraception below. 
For non-commercial use only


Brigatinib 
 
Study No. Brigatinib-1004 
Page 64 of 64 
Protocol Incorporating Amendment No. 01 
05 Jan 2024 
 
CONFIDENTIAL 
The following procedures apply for contraception and pregnancy avoidance: 
Highly effective methods of contraception are defined as “those, alone or in combination, that 
result in a low failure rate (ie, less than 1% failure rate per year when used consistently and 
correctly). Females of reproductive potential should be advised to use effective 
non-hormonal contraception during treatment with brigatinib and for at least 4 months 
following the final dose of brigatinib USPI. 
Change 8. Text was updated to correct a missing infinity symbol from a PK parameter 
(Section 1.0 - STUDY SUMMARY, Sample Size Justification) 
Rationale for the change: Correction to PK parameter symbol. 
Update in strikethrough for text removed and in bold for text added  
The sample size calculation was based on the expected 2-sided 90% CIs for the difference in 
the paired, ln-transformed AUC    means of brigatinib after administration as an oral solution 
versus an immediate-release tablet. The within-subject percent coefficient of variation (%CV) 
for brigatinib AUC   was estimated to be 12% on the basis of data from previous clinical 
studies conducted in healthy subjects (Studies AP26113-15-106 and AP26113-16-110). If the 
observed GMR for brigatinib AUC   after administration as an oral solution versus a tablet is 
1, with a sample size of 8, the 90% CIs for the GMR is expected to be 0.89 to 1.12 on the basis 
of the variance assumptions. 
It is anticipated that a total of approximately 12 subjects will be enrolled to obtain at least 
8 PK-evaluable subjects. Subjects will be randomized into 2 treatment sequences, as indicated 
in Table 1.a. 
Change 9. Verbiage was updated to correct a protocol discrepancy (Section 3.0 - Schedule of 
Study Procedures [Footnote “i”] and Section 9.2.9.1 - Clinical Laboratory Tests) 
Rationale for the change: A protocol clarification letter (dated 28 November 2023) was written 
and submitted detailing an exemption from the fasting requirement for the laboratory 
assessment (chemistry) scheduled at Hour 8 on Day 1, as there will be a meal served less than 
8 hours prior to the laboratory assessment. 
Updated text in bold. 
Serum chemistry tests will be performed after at least an 8-hour fast with the exception of the 
Hour 8 postdose laboratory assessment on Day 1; however, in case of dropouts or rechecks, 
subjects may not have fasted for 8 hours prior to when the serum chemistry sample is being 
taken. 
Change 10. Section 14.1.4 – List of Abbreviations 
Section was updated to include abbreviation, USPI (United States Prescribing Information). 
 
For non-commercial use only


Signature Page for Brigatinib-1004 Protocol Amend 1 2024-01-05
Title: Amend 1 to A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period, Cros
Document Number: TDN-000230049 v1.0
Approval
Clinical
05-Jan-2024 14:03:21 GMT+0000
Approval
Clinical
05-Jan-2024 15:14:33 GMT+0000
Approval
Statistics
05-Jan-2024 16:52:11 GMT+0000
For non-commercial use only

SAP_001.pdf: 
For non-commercial use only


STATISTICAL ANALYSIS PLAN 
Study Number: Brigatinib-1004 
A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the 
Relative Bioavailability of Brigatinib Administered as an Oral Solution versus an 
Immediate-Release Tablet in Adult Healthy Subjects 
Phase: 1 
Version: Final 
Date: 03 Nov 2023 
Prepared by: 
, MS 
Data Management and Biometrics 
Celerion 
, MS 
, Clinical Pharmacology & Pharmacometrics 
Data Management and Biometrics 
Celerion 
Based on: 
Protocol Version: Original 
Protocol Date: 13 Sep 2023 
CONFIDENTIAL PROPERTY OF TAKEDA 
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement 
by the recipient that no information contained herein will be published or disclosed without written authorization 
from Takeda. 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 2 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
REVISION HISTORY 
Version  
Approval Date 
Primary Rationale for Revision 
Original version 
3-Nov-2023 
Not Applicable 
 
 
 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 3 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
APPROVAL SIGNATURE 
Study Title: 
A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period, Crossover 
Study to Evaluate the Relative Bioavailability of Brigatinib Administered 
as an Oral Solution versus an Immediate-Release Tablet in Adult Healthy 
Subjects 
 
Approvals: 
As the statistical analysis plan was executed using the Veeva platform, please find the 
e-signature page at the end of the document. 
 
Signature:
 
 
 PhD. 
 Statistical and Quantitative Sciences 
Takeda Development Center Americas, Inc. 
 
 
 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 4 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
TABLE OF CONTENTS 
1.0 
OBJECTIVES, ENDPOINTS AND ESTIMANDS ............................................................8 
1.1 
Objectives ......................................................................................................................8 
1.1.1 
Primary Objective ..................................................................................................8 
1.1.2 
Secondary Objective ..............................................................................................8 
1.2 
Endpoints .......................................................................................................................8 
1.2.1 
Primary Endpoints .................................................................................................8 
1.2.2 
Secondary Endpoint ...............................................................................................8 
1.2.3 
Exploratory Endpoints ...........................................................................................8 
1.2.4 
Additional Endpoints .............................................................................................9 
1.3 
Estimands .......................................................................................................................9 
2.0 
STUDY DESIGN.................................................................................................................9 
3.0 
STATISTICAL HYPOTHESES AND DECISION RULES .............................................10 
3.1 
Statistical Hypotheses ..................................................................................................10 
3.2 
Statistical Decision Rules ............................................................................................11 
3.3 
Multiplicity Adjustment ...............................................................................................11 
4.0 
SAMPLE-SIZE DETERMINATION ................................................................................11 
5.0 
ANALYSIS SETS .............................................................................................................11 
5.1 
Safety Set .....................................................................................................................11 
5.2 
PK Set ..........................................................................................................................11 
6.0 
STATISTICAL ANALYSIS .............................................................................................11 
6.1 
General Considerations ................................................................................................11 
6.1.1 
Handling of Treatment Misallocations ................................................................13 
6.2 
Study Information ........................................................................................................13 
6.3 
Disposition of Subjects ................................................................................................13 
6.4 
Demographic and Other Baseline Characteristics .......................................................14 
6.4.1 
Demographics ......................................................................................................14 
6.4.2 
Medical History and Concurrent Medical Conditions .........................................14 
6.5 
Medication History and Concomitant Medications .....................................................14 
6.6 
Efficacy Analysis .........................................................................................................14 
6.7 
Safety Analysis ............................................................................................................15 
6.7.1 
Adverse Events ....................................................................................................15 
6.7.2 
Adverse Events of Special Interest ......................................................................16 
6.7.3 
Clinical Laboratory Evaluation ...........................................................................16 
6.7.4 
Vital Signs ...........................................................................................................17 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 5 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
6.7.5 
12-Lead Electrocardiogram .................................................................................18 
6.7.6 
Palatability Assessment (Treatment A) ...............................................................18 
6.7.7 
Physical Examinations .........................................................................................19 
6.7.8 
Overdose ..............................................................................................................19 
6.7.9 
Extent of Exposure and Compliance ...................................................................19 
6.8 
Pharmacokinetic Analysis ............................................................................................19 
6.9 
Patient Reported Outcomes (PROs) and Health Care Utilization Endpoints 
Analysis........................................................................................................................20 
6.10 
Interim Analyses ..........................................................................................................20 
6.11 
Preliminary Analysis ....................................................................................................20 
6.12 
Data Monitoring Committee/Internal Review Committee/ [Other Data Review 
Committees] .................................................................................................................20 
7.0 
REFERENCES ..................................................................................................................20 
8.0 
CHANGES TO PROTOCOL PLANNED ANALYSES ...................................................20 
9.0 
APPENDIX ........................................................................................................................21 
9.1 
Changes From the Previous Version of the SAP .........................................................21 
9.2 
Data Handling Conventions .........................................................................................21 
9.3 
Analysis Software ........................................................................................................21 
 
LIST OF IN-TEXT TABLES 
Table 2.a: 
Study Schematic.......................................................................................................9 
Table 2.b 
Description of Treatment Sequences in the Study .................................................10 
Table 2.c 
Planned Brigatinib Dose Levels/Treatments .........................................................10 
Table 6.a 
Collection of Laboratory Samples .........................................................................16 
Table 6.b 
Collection of Vital Signs ........................................................................................17 
Table 6.c 
Collection of ECGs ................................................................................................18 
Table 6.d 
Collection of Blood Samples for Pharmacokinetic Analysis .................................19 
 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 6 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
ABBREVIATIONS 
λz 
terminal disposition phase rate constant 
AE 
adverse event 
AESI 
adverse event of special interest 
AUC 
area under the plasma concentration-time curve from time 0 to infinity, calculated 
using the observed value of the last quantifiable concentration 
AUC∞_pred 
area under the plasma concentration-time curve from time 0 to infinity, calculated 
using the predicted value of the last quantifiable concentration 
AUCextrap% 
area under the curve from the last quantifiable plasma concentration to infinity, 
calculated using the observed value of the last quantifiable concentration, expressed 
as a percentage of AUC∞ 
AUCextrap%_pred 
area under the curve from the last quantifiable plasma concentration to infinity, 
calculated using the predicted value of the last quantifiable concentration, expressed 
as a percentage of AUC∞_pred 
AUClast 
area under the plasma concentration-time curve from time 0 to the last quantifiable 
concentration 
BLQ 
below the lower limit of quantitation 
BMI 
body mass index 
CI 
confidence interval 
CL/F 
apparent clearance after extravascular administration, calculated using the observed 
value of the last quantifiable concentration 
CL/F_pred 
apparent clearance after extravascular administration, calculated using the predicted 
value of the last quantifiable concentration  
Cmax 
maximum observed plasma concentration  
COVID-19 
coronavirus disease 2019 
CPAP 
clinical pharmacology analysis plan 
CRF 
case report form 
CRU 
Clinical Research Unit 
CSR 
clinical study report 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
coefficient of variation 
DMP 
data management plan 
ET 
early termination 
ECG 
electrocardiogram 
Geom CV 
geometric coefficient of variation 
Geom Mean 
geometric mean 
GMR 
geometric least-squares mean ratio 
ICF 
Informed Consent Form 
ln 
natural logarithm 
LSM 
least-squares mean 
Mean 
arithmetic mean 
MedDRA® 
Medical Dictionary for Regulatory Activities® 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 7 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
n 
number of observations 
PK 
pharmacokinetic(s) 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SD 
standard deviation 
SEM 
standard error of the mean 
SOC 
system organ class 
t½z 
terminal disposition phase half-life 
TEAE 
treatment-emergent adverse event 
TFL 
table, figure, and listing 
tmax 
time of first occurrence of Cmax 
Vz/F 
apparent volume of distribution during the terminal disposition phase after 
extravascular administration, calculated using the observed value of the last 
quantifiable concentration 
Vz/F_pred 
apparent volume of distribution during the terminal disposition phase after 
extravascular administration, calculated using the predicted value of the last 
quantifiable concentration 
WHO 
World Health Organization 
 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 8 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
1.0 
OBJECTIVES, ENDPOINTS AND ESTIMANDS 
1.1 
Objectives 
1.1.1 
Primary Objective 
To determine the relative bioavailability of brigatinib after single-dose administration of an oral 
solution formulation versus an immediate-release tablet formulation. 
1.1.2 
Secondary Objective 
To evaluate the safety and tolerability of brigatinib after single-dose administration of an oral 
solution formulation and an immediate-release tablet formulation. 
1.2 
Endpoints 
1.2.1 
Primary Endpoints 
The primary endpoints for this study are brigatinib pharmacokinetic (PK) parameters after a 
single-dose of an oral solution formulation and an immediate-release tablet formulation, 
including: 
• Maximum observed plasma concentration (Cmax) 
• Area under the plasma concentration-time curve from time 0 to time of the last 
quantifiable concentration (AUClast) 
• Area under the plasma concentration-time curve from time 0 to infinity, calculated using 
the observed value of the last quantifiable concentration (AUC) 
1.2.2 
Secondary Endpoint  
The secondary endpoints will be assessed through evaluation of the following parameters:  
• Number of subjects with at least one treatment-emergent adverse event (TEAE) and/or 
severe adverse event (SAE). 
1.2.3 
Exploratory Endpoints 
The following PK parameters for brigatinib after administration of each formulation: 
• Time of the first occurrence of Cmax (tmax) 
• Apparent clearance after extravascular administration, calculated using the observed 
value of the last quantifiable concentration (CL/F) 
• Apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated using the observed value of the last quantifiable concentration 
(Vz/F) 
• Terminal disposition phase half-life (t½z) 
• Terminal disposition phase rate constant (λz) 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 9 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
• Area under the curve from the last quantifiable plasma concentration to infinity, 
calculated using the observed value of the last quantifiable concentration, expressed as a 
percentage of AUC∞ (AUCextrap%) 
Data related to the acceptability and palatability of the oral solution formulation will also be 
collected. 
1.2.4 
Additional Endpoints  
• Area under the plasma concentration-time curve from time 0 to infinity, calculated using the 
predicted value of the last quantifiable concentration (AUC∞_pred) 
• Apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated using the predicted value of the last quantifiable concentration 
(Vz/F_pred) 
• Apparent clearance after extravascular administration, calculated using the predicted value of 
the last quantifiable concentration (CL/F_pred) 
• Area under the curve from the last quantifiable plasma concentration to infinity, calculated 
using the predicted value of the last quantifiable concentration, expressed as a percentage of 
AUC∞_pred (AUCextrap%_pred) 
1.3 
Estimands 
Not applicable. 
2.0 
STUDY DESIGN 
This is an open-label, randomized, 2-period, 2-sequence, crossover study in healthy adult 
subjects to evaluate the relative bioavailability of brigatinib when administered as an oral 
solution versus as an immediate-release tablet (ALUNBRIG®). A study schematic is shown in 
Table 2.a. 
Table 2.a: 
Study Schematic 
Pretreatment 
Treatment Periods 1 & 2 (a) 
Follow-up (c) 
Screening 
Check-in (b) 
(Periods 1 & 2) 
Dosing and 
Study Assessments 
PK Assessments 
Within 28 
days of first 
dosing 
Day -1 
Day 1 
Days 1-4 (d) 
Days 6 & 8 (d) 
14 (±2) Days 
following last 
dose 
 
 Confinement (d)       
 
 
  
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 10 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
• Treatment A (test formulation): 90 mg oral solution dose of brigatinib administered in a 
fasted state 
• Treatment B (reference formulation): 90 mg tablet dose of brigatinib administered in a 
fasted state 
Approximately 12 subjects will be randomly assigned in a 1:1 ratio to one of the treatment 
sequences, as part of a crossover design (Table 2.b): 
Table 2.b 
Description of Treatment Sequences in the Study 
Sequence 
Approximate number of 
subjects 
Period 1 
Period 2 
AB 
6 
A 
B 
BA 
6 
B 
A 
A= Oral solution dose of brigatinib, fasted state; B= Tablet dose of brigatinib, fasted state. 
Subjects will be admitted to the clinical facility on Day -1, the day prior to brigatinib 
administration in each dosing period. On Day 1 of each period, a single 90 mg dose of brigatinib 
will be administered. Blood samples for the measurement of plasma concentrations of brigatinib 
will be collected predose and up to 168 hours postdose following each brigatinib dose. For each 
dosing period, subjects will be housed starting on Day -1, at the time indicated by the clinical 
research unit (CRU), until the morning of Day 4 after the 72 hour postdose blood draw and/or 
study procedures. There will be a washout period of at least 14 days between brigatinib 
administration in each study period. Subjects will return for dosing and/or study procedures. At 
all times, a subject may be required to remain at the CRU for longer at the discretion of the 
Investigator or designee. As per site preference, subjects may be confined throughout the study 
(ie, washout period and/or return visit[s]).  
The follow-up contact will occur 14 (±2) days post the last dose of study drug by telephone. If 
abnormal, potentially clinically significant findings are noted during this phone follow-up, 
subjects may then be brought back to the clinic for re-evaluation per the Investigator’s 
discretion. SAEs should be followed up until resolution or permanent outcome. 
The planned dose levels/treatments of brigatinib to be evaluated are outlined in Table 2.c.  
Table 2.c 
Planned Brigatinib Dose Levels/Treatments 
Treatment 
Brigatinib Dose 
Formulation 
State 
A 
90 mg 
Oral Solution 
Fasted 
B 
90 mg 
Tablet 
Fasted 
3.0 
STATISTICAL HYPOTHESES AND DECISION RULES  
3.1 
Statistical Hypotheses 
Not applicable. 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 11 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
3.2 
Statistical Decision Rules 
Not applicable. 
3.3 
Multiplicity Adjustment 
Not applicable. 
4.0 
SAMPLE-SIZE DETERMINATION 
The sample size calculation was based on the expected 2-sided 90% confidence intervals (CIs) 
for the difference in the paired, natural logarithm (ln)-transformed AUC means of brigatinib 
after administration as an oral solution versus an immediate-release tablet. The within-subject 
percent coefficient of variation (CV%) for brigatinib AUC was estimated to be 12% on the basis 
of data from previous clinical studies conducted in healthy subjects (Studies AP26113-15-106 
and AP26113-16-110). If the observed geometric mean ratio (GMR) for brigatinib AUC after 
administration as an oral solution versus a tablet is 1, with a sample size of 8, the 90% CIs for 
the GMR is expected to be 0.89 to 1.12 on the basis of the variance assumptions. It is anticipated 
that a total of approximately 12 subjects will be enrolled to obtain at least 8 PK-evaluable 
subjects. Subjects will be randomized into 2 treatment sequences, as indicated in Table 2.b. 
5.0 
ANALYSIS SETS 
5.1 
Safety Set 
All subjects who received at least one dose of the study drug will be included in the safety 
evaluations. 
5.2 
PK Set  
All subjects who comply sufficiently with the protocol and display an evaluable PK profile (eg, 
exposure to treatment, availability of measurements and absence of major protocol violations) 
will be included in the statistical analyses. 
6.0 
STATISTICAL ANALYSIS  
6.1 
General Considerations 
All PK analyses will be conducted using Phoenix® WinNonlin® Version 8.3.4, or higher. All 
statistical analyses will be conducted using SAS® Version 9.4 or higher. All relevant data 
recorded in the case report form (CRF) and clinical laboratory data will be listed by subject and 
treatment. All table, figure, and listing (TFL) shells and numbering list will be included and 
specified in the TFL Shells document.  
For PK data, the number of observations (n) will be presented as an integer (no decimal places), 
arithmetic mean (mean), median, and geometric mean (geom mean) values will be presented to 1 
more level of precision than the individual values. Standard deviation (SD) and standard error of 
the mean (SEM) will be presented to 2 more levels of precision than the individual values. 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 12 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
Minimum and maximum values will be presented to the same precision as the individual values. 
Arithmetic percent coefficient of variation (CV%) and geometric percent coefficient of variation 
(geom CV%) will be presented to 1 decimal place. 
Geometric least-squares means (LSMs) will be reported with 1 more level of precision than the 
individual data. GMRs and 90% CIs for the GMRs will be reported to 2 decimal places. 
Intra-subject CV%s will be reported to 1 decimal place. 
Noncompartmental analyses of PK parameters will be used in this study. Concentration values 
below the lower limit of quantitation (BLQ) will be presented as ‘BLQ’ in the concentration 
table listings and footnoted accordingly. BLQ values will be treated as zero for the calculation of 
summary statistics, the generation of concentration plots, and the calculation of PK parameters, 
unless they are deemed questionable (eg, BLQ value between measurable values), in which case 
they will be treated as missing and excluded from the concentration summary statistics and the 
PK analysis. BLQ values treated as missing/excluded from the summary statistics and PK 
analysis will be footnoted accordingly. Values of 0 will not be included in the calculation of 
geom mean and geom CV%.  
A subject’s PK parameter data will be included in the listings, but may be excluded from the 
descriptive and inferential statistics if one or more of the following criteria are met: 
• A predose (0 hour) concentration is greater than 5% of that subject’s Cmax value for the same 
treatment 
• A subject did not meet inclusion/exclusion criteria that may have an effect on brigatinib PK 
(as determined by the Takeda Clinical Pharmacology Lead and Celerion Pharmacokinetic 
Scientist) 
• A subject deviates substantially from the protocol defined study procedures, including but 
not limited to dosing, dose timing, sample collection, meal timing, etc (as determined by the 
Takeda Clinical Pharmacology Lead and Celerion Pharmacokinetic Scientist)  
• A subject may be excluded due to vomiting within twice the median tmax of brigatinib (2 × ~2 
hours = 4 hours) 
The details on PK parameter calculations and TFLs will be outlined in the clinical pharmacology 
analysis plan (CPAP) and TFL Shells document including specifics on the following: 
• Insufficient data to determine a reliable t1/2z value and other λz-dependent parameters  
• PK parameters presented by treatment, including the units, precision, and summary statistics 
that will be presented in in-text and end-of-text tables 
• Concentration data presented by treatment, including the units, precision, and summary 
statistics that will be presented in end-of-text tables 
• Concentration data file used for PK analysis 
• PK parameter Phoenix® WinNonlin® output file used to generate the TFLs 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 13 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
• PK parameter ratios for Cmax, AUClast, AUC∞, AUC∞_pred presented in end-of-text tables. 
• Linear mixed-effects model results presented in in-text and end-of-text tables 
• Arithmetic mean concentration-time figures presented as in-text and end-of-text figures 
• Listings of concentration data for individual subjects in Appendix 16.2.5 of the clinical study 
report (CSR). 
• Individual concentration-time figures presented in Appendix 16.2.6 of the CSR. 
Continuous demographic and safety data will be summarized descriptively. For categorical 
variables, the count and percentages of each reported value will be tabulated, where applicable. 
The denominator for the percent calculation will be the number of subjects in the safety set for 
overall summaries, and the number of subjects dosed with each treatment in by-treatment 
summaries. For continuous variables, n, mean, SD, minimum, median, and maximum values will 
be tabulated. The level of precision will be presented as follows: minimum/maximum in the 
same precision as in the database, mean/median in one more precision level than 
minimum/maximum, SD in one more precision level than mean/median, and n will be presented 
as an integer. Counts and percentages will be presented as integers. Unless otherwise stated, 
baseline is defined as the last observation, including recheck or unscheduled events, prior to 
dosing in each period. 
6.1.1 
Handling of Treatment Misallocations 
Subjects with any treatment misallocations will be analyzed based on the treatment the subjects 
actually received. 
6.2 
Study Information 
A study information table will be generated including the following items: date of first subject’s 
signed informed consent form (ICF), date of first dose of brigatinib, date of last dose of 
brigatinib, date of last subject’s discontinuation, date of last subject’s last procedure for 
collection of data for primary endpoint, the version of Medical Dictionary for Regulatory 
Activities (MedDRA®), the version of World Health Organization (WHO) Drug Dictionary, and 
SAS version used for creating the datasets. 
6.3 
Disposition of Subjects 
Disposition of all randomized subjects (number of subjects who dosed, completed the study, 
discontinued from the study, and reason(s) for discontinuation(s)) will be summarized by 
randomized treatment sequence and overall. Treatment sequence, study completion status, date 
of completion, and whether brigatinib was discontinued will be listed by subject. Reasons for 
discontinuation of brigatinib and/or study and dates of discontinuation will be listed, if 
applicable.  
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 14 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
6.4 
Demographic and Other Baseline Characteristics 
6.4.1 
Demographics 
Demographic and baseline characteristics will be summarized by randomized treatment sequence 
and overall based on the safety set. Summary statistics (n, mean, SD, minimum, median, and 
maximum) will be generated for continuous variables (age, weight, height, and body mass index 
[BMI]) and the number and percentages of subjects within each category will be presented for 
categorical variables (sex, race, and ethnicity). The last height, weight, and BMI measured prior 
to dosing will be used in the summaries. All demographic data will be listed by subject as 
recorded on the CRF, including date of informed consent and protocol version. 
6.4.2 
Medical History and Concurrent Medical Conditions 
Medical history will include any significant conditions or diseases that resolved at or before 
signing the ICF. All medical history reported by the subject will be recorded regardless of when 
it may have occurred. Concurrent medical conditions are those significant ongoing conditions or 
diseases that are present at signing the ICF. Medical history and concurrent medical conditions 
will be listed based on safety set. 
Any medical condition starting or worsening after taking the first dose of brigatinib will be 
classified as a TEAE. All medical history will be coded using MedDRA® version specified in the 
data management plan (DMP). If available, the medical history and concurrent medical condition 
listings will include the coded term (preferred term and system organ class [SOC]), start date (if 
known) and end date (if known) or whether the condition was ongoing, and a description of the 
condition or event. No summaries or statistical analysis will be performed for these data. 
6.5 
Medication History and Concomitant Medications  
Medication history includes any relevant medication stopped at or within 28 days before signing 
the ICF. Concomitant medication includes any medication other than brigatinib taken at any time 
between screening and the end of the study (including follow-up contact). All medication history 
and concomitant medications recorded during the study will be coded with the WHO Drug 
Dictionary version specified in the DMP and listed based on the safety set. If available, the 
listings will include the medication name, coded term, dosage, route of administration, start date 
and time (if known), end date and time (if known), or whether it continued after study 
completion, and indication for use. No summaries or statistical analysis will be performed for 
these data.  
6.6 
Efficacy Analysis 
Not applicable 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 15 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
6.7 
Safety Analysis 
Safety will be evaluated by the incidence of TEAEs, severity and relationship(s) of TEAEs, and 
changes from baseline in the subjects’ clinical laboratory results, vital signs, and 12-lead 
electrocardiograms (ECGs) using the safety set. Clinically significant laboratory values and vital 
signs will be reported as AEs, as applicable. All safety data will be listed by subject, treatment, 
and assessment time points, including rechecks, unscheduled assessments, and early termination 
(ET), chronologically. 
Continuous variables will be summarized using n, mean, SD, minimum, median, and maximum. 
Frequency counts and percentages will be reported for categorical data when appropriate. Where 
individual data points are missing because of dropouts or other reasons, the data will be 
summarized based on reduced denominators. Postdose recheck, unscheduled, or ET results will 
not be used in summaries. 
Tables summarizing safety data by assessment time point will only include summaries for 
baseline and post-baseline time points. 
6.7.1 
Adverse Events 
All AEs captured in the database will be listed in by-subject data listings including verbatim 
term, coded term, severity according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0, relationship to brigatinib (related or not 
related), frequency, outcome, dates and times of onset and resolution, and action relative to the 
AE as recorded in the CRF. Study procedure taken due to AE will also be listed. All AEs 
occurring during this study will be coded using the MedDRA® version specified in the DMP. 
Only TEAEs will be summarized. 
A TEAE is defined as an AE that is starting or worsening at the time of or after the first dose of 
brigatinib administered in the study. Each TEAE will be attributed to the treatment prior to and 
the closest to the AE based on the AE onset date and time. 
If the onset time of an AE is missing and the onset date is the same as a treatment dosing date, 
then the AE will be counted under the treatment given on the same day. If onset time of an AE is 
missing and the onset date does not fall on a dosing date, then the AE will be considered 
treatment emergent for the most recent treatment administered. If the onset date of an AE is 
missing, then the AE will be considered treatment-emergent and attributed to the first treatment 
received. If severity is missing, the AE will be counted as severe (Grade 3), and if relationship is 
missing, the AE will be counted as related.  
TEAEs will be tabulated by treatment (including overall), SOC, and preferred term. Summary 
tables will include number of subjects reporting the TEAE as percent of safety set by treatment 
and overall. The most commonly reported non-serious TEAEs (i.e., those events reported by >1 
subject in any treatment, excluding serious adverse events (SAEs) will also be summarized. The 
denominators for percent calculations will be the number of subjects dosed for each treatment. In 
addition, TEAEs will be summarized as number of TEAEs and percentage of TEAEs for each 
treatment and overall.  
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


For non-commercial use only


For non-commercial use only


For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 19 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
6.7.7 
Physical Examinations 
Full physical examinations will be performed at screening, check-in and 8 hours post-dose in 
each period, and on Day 8 of Period 2. Additional physical examinations may be performed at 
other times at the discretion of the Investigator. Physical examination findings will be presented 
in the data listings by subject. 
6.7.8 
Overdose 
All cases of overdose will be presented in a data listing by subject. Any AEs associated with 
overdose will be documented. 
6.7.9 
Extent of Exposure and Compliance 
The dates, times, and doses of brigatinib will be listed by subject and study period. 
6.8 
Pharmacokinetic Analysis 
Blood samples for assessment of plasma brigatinib concentrations will be collected as outlined in 
Table 6.d below:  
Table 6.d 
Collection of Blood Samples for Pharmacokinetic Analysis 
Analyte Matrix 
Period 
Scheduled Time (Hours)* 
Brigatinib Plasma 
1 and 2 
Predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 120, and 168 
hours postdose. 
*The actual date and time of sample collection will be recorded on the source document in the CRF. 
Plasma concentrations of brigatinib will be listed and summarized descriptively by treatment and 
PK sampling time using the following descriptive statistics: n, mean, SD, CV%, SEM, minimum, 
median, and maximum. Excluded concentrations will be presented and footnoted as such in the 
concentration table listings, and those values will be excluded from the descriptive statistics.  
Individual subject concentration-time profiles will be plotted by treatment on linear and semi-log 
scales. The arithmetic mean profiles of the concentration-time data will be plotted by treatment 
on linear (with and without SD) and semi-log scales. For summary statistics and arithmetic mean 
concentration-time plots, the nominal PK sampling time will be used. For individual subject 
concentration-time plots, the actual PK sampling time will be used. 
The PK parameters will be calculated from plasma brigatinib concentration-time profiles using 
non-compartmental analysis methods where all calculations will be based on actual sampling 
times after brigatinib dosing. The PK parameters will be summarized by treatment using the 
following descriptive statistics: n, mean, SD, CV%, SEM, minimum, median, maximum, geom 
mean, and geom CV%. Excluded parameters will be presented and footnoted as such in the PK 
parameter table listings, and those values will be excluded from the descriptive statistics. 
A linear mixed-effects analysis of variance model will be used for the analysis on the 
ln-transformed brigatinib PK parameters (Cmax, AUClast, AUC, and AUC∞_pred). The model will 
include sequence, treatment, and period as fixed effects. Subject nested within sequence will be 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 20 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
included as a random effect. Each model will include calculation of LSM as well as the 
difference between treatment LSM. Geometric mean ratios and 90% CIs will be calculated using 
the exponentiation of the difference between treatment LSM from the analyses on the 
ln-transformed Cmax, AUClast, AUC, and AUC∞_pred. These ratios will be expressed as a ratio of test 
treatment (ie, oral solution, Treatment A) relative to the reference treatment (ie, tablet, 
Treatment B). 
The following SAS code will be used to perform the analysis: 
PROC MIXED; 
CLASS TREAT PERIOD SEQUENCE SUBJECT; 
MODEL LN<Parameter> = TREAT PERIOD SEQUENCE / DDFM = KR; 
RANDOM SUBJECT(SEQUENCE); 
ESTIMATE “Treatment A vs Treatment B” TREAT 1 -1 / CL ALPHA=0.1 E; 
RUN; 
6.9 
Patient Reported Outcomes (PROs) and Health Care Utilization Endpoints 
Analysis 
Not applicable. 
6.10 
Interim Analyses 
Not applicable. 
6.11 
Preliminary Analysis 
A preliminary PK analysis will be completed as described in the CPAP and Section 6.8 of the 
SAP, with the following changes: 1) QCed data will be used (not QAed); 2) nominal times (not 
actual sampling times) will be used to calculate PK parameters; and 3) tables and figures will be 
created using Phoenix® WinNonlin® Version 8.3.4 or higher. 
6.12 
Data Monitoring Committee/Internal Review Committee/ [Other Data Review 
Committees] 
Not applicable. 
7.0 
REFERENCES 
Not applicable. 
8.0 
CHANGES TO PROTOCOL PLANNED ANALYSES 
This SAP is aligned with the analysis planned in the protocol. 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only


Brigatinib-1004 
Celerion Study Number CA29913 
Page 21 of 21
Statistical Analysis Plan 
03 Nov 2023
 
CONFIDENTIAL 
9.0 
APPENDIX  
9.1 
Changes From the Previous Version of the SAP 
Not applicable. 
9.2 
Data Handling Conventions  
Not applicable. 
9.3 
Analysis Software  
SAS® Version 9.4 or higher will be used for all statistical analyses provided in the CSR. 
 
Celerion ClinicalVault  Doc# VV-TMF-268877  V1.0
For non-commercial use only